A status with BODY WEIGHT that is grossly above the acceptable or desirable weight, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.
A condition of having excess fat in the abdomen. Abdominal obesity is typically defined as waist circumferences of 40 inches or more in men and 35 inches or more in women. Abdominal obesity raises the risk of developing disorders, such as diabetes, hypertension and METABOLIC SYNDROME X.
BODY MASS INDEX in children (ages 2-12) and in adolescents (ages 13-18) that is grossly above the recommended cut-off for a specific age and sex. For infants less than 2 years of age, obesity is determined based on standard weight-for-length percentile measures.
An indicator of body density as determined by the relationship of BODY WEIGHT to BODY HEIGHT. BMI=weight (kg)/height squared (m2). BMI correlates with body fat (ADIPOSE TISSUE). Their relationship varies with age and gender. For adults, BMI falls into these categories: below 18.5 (underweight); 18.5-24.9 (normal); 25.0-29.9 (overweight); 30.0 and above (obese). (National Center for Health Statistics, Centers for Disease Control and Prevention)
A status with BODY WEIGHT that is above certain standard of acceptable or desirable weight. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal "over fat".
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
Specialized connective tissue composed of fat cells (ADIPOCYTES). It is the site of stored FATS, usually in the form of TRIGLYCERIDES. In mammals, there are two types of adipose tissue, the WHITE FAT and the BROWN FAT. Their relative distributions vary in different species with most adipose tissue being white.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
A 16-kDa peptide hormone secreted from WHITE ADIPOCYTES. Leptin serves as a feedback signal from fat cells to the CENTRAL NERVOUS SYSTEM in regulation of food intake, energy balance, and fat storage.
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time.
Decrease in existing BODY WEIGHT.
Agents that increase energy expenditure and weight loss by neural and chemical regulation. Beta-adrenergic agents and serotoninergic drugs have been experimentally used in patients with non-insulin dependent diabetes mellitus (NIDDM) to treat obesity.
The amount of fat or lipid deposit at a site or an organ in the body, an indicator of body fat status.
Regular course of eating and drinking adopted by a person or animal.
The measurement around the body at the level of the ABDOMEN and just above the hip bone. The measurement is usually taken immediately after exhalation.
A plant family of the order Geraniales, subclass Rosidae, class Magnoliopsida.
Increase in BODY WEIGHT over existing weight.
A cluster of metabolic risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome X include excess ABDOMINAL FAT; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state. (from AHA/NHLBI/ADA Conference Proceedings, Circulation 2004; 109:551-556)
Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time.
The chemical reactions involved in the production and utilization of various forms of energy in cells.
Fats present in food, especially in animal products such as meat, meat products, butter, ghee. They are present in lower amounts in nuts, seeds, and avocados.
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
A state of insufficient flesh on the body usually defined as having a body weight less than skeletal and physical standards. Depending on age, sex, and genetic background, a BODY MASS INDEX of less than 18.5 is considered as underweight.
HYPOVENTILATION syndrome in very obese persons with excessive ADIPOSE TISSUE around the ABDOMEN and DIAPHRAGM. It is characterized by diminished to absent ventilatory chemoresponsiveness; chronic HYPOXIA; HYPERCAPNIA; POLYCYTHEMIA; and long periods of sleep during day and night (HYPERSOMNOLENCE). It is a condition often related to OBSTRUCTIVE SLEEP APNEA but can occur separately.
Mutant mice exhibiting a marked obesity coupled with overeating, hyperglycemia, hyperinsulinemia, marked insulin resistance, and infertility when in a homozygous state. They may be inbred or hybrid.
The relative amounts of various components in the body, such as percentage of body fat.
The waist circumference measurement divided by the hip circumference measurement. For both men and women, a waist-to-hip ratio (WHR) of 1.0 or higher is considered "at risk" for undesirable health consequences, such as heart disease and ailments associated with OVERWEIGHT. A healthy WHR is 0.90 or less for men, and 0.80 or less for women. (National Center for Chronic Disease Prevention and Health Promotion, 2004)
A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).
The technique that deals with the measurement of the size, weight, and proportions of the human or other primate body.
Ingestion of a greater than optimal quantity of food.
The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed)
The consumption of edible substances.
Total number of calories taken in daily whether ingested or by parenteral routes.
Glucose in blood.
Behavioral responses or sequences associated with eating including modes of feeding, rhythmic patterns of eating, and time intervals.
Surgical procedures aimed at affecting metabolism and producing major WEIGHT REDUCTION in patients with MORBID OBESITY.
Cells in the body that store FATS, usually in the form of TRIGLYCERIDES. WHITE ADIPOCYTES are the predominant type and found mostly in the abdominal cavity and subcutaneous tissue. BROWN ADIPOCYTES are thermogenic cells that can be found in newborns of some species and hibernating mammals.
A melanocortin receptor subtype found primarily in BRAIN. It shows specificity for ALPHA-MSH; BETA-MSH and ADRENOCORTICOTROPIC HORMONE.
Typical way of life or manner of living characteristic of an individual or group. (From APA, Thesaurus of Psychological Index Terms, 8th ed)
Fatty tissue in the region of the ABDOMEN. It includes the ABDOMINAL SUBCUTANEOUS FAT and the INTRA-ABDOMINAL FAT.
Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING).
Maleness or femaleness as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or effect of a circumstance. It is used with human or animal concepts but should be differentiated from SEX CHARACTERISTICS, anatomical or physiological manifestations of sex, and from SEX DISTRIBUTION, the number of males and females in given circumstances.
Fatty tissue inside the ABDOMINAL CAVITY, including visceral fat and retroperitoneal fat. It is the most metabolically active fat in the body and easily accessible for LIPOLYSIS. Increased visceral fat is associated with metabolic complications of OBESITY.
Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
Physical activity which is usually regular and done with the intention of improving or maintaining PHYSICAL FITNESS or HEALTH. Contrast with PHYSICAL EXERTION which is concerned largely with the physiologic and metabolic response to energy expenditure.
Cell surface receptors for obesity factor (LEPTIN), a hormone secreted by the WHITE ADIPOCYTES. Upon leptin-receptor interaction, the signal is mediated through the JAK2/STAT3 pathway to regulate food intake, energy balance and fat storage.
The spatial arrangement of the atoms of a nucleic acid or polynucleotide that results in its characteristic 3-dimensional shape.
Polypeptides produced by the ADIPOCYTES. They include LEPTIN; ADIPONECTIN; RESISTIN; and many cytokines of the immune system, such as TUMOR NECROSIS FACTOR-ALPHA; INTERLEUKIN-6; and COMPLEMENT FACTOR D (also known as ADIPSIN). They have potent autocrine, paracrine, and endocrine functions.
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
A 30-kDa COMPLEMENT C1Q-related protein, the most abundant gene product secreted by FAT CELLS of the white ADIPOSE TISSUE. Adiponectin modulates several physiological processes, such as metabolism of GLUCOSE and FATTY ACIDS, and immune responses. Decreased plasma adiponectin levels are associated with INSULIN RESISTANCE; TYPE 2 DIABETES MELLITUS; OBESITY; and ATHEROSCLEROSIS.
The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds.
The characteristic three-dimensional shape of a molecule.
Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures.
Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
The physical activity of a human or an animal as a behavioral phenomenon.
Fatty tissue composed of WHITE ADIPOCYTES and generally found directly under the skin (SUBCUTANEOUS FAT) and around the internal organs (ABDOMINAL FAT). It has less vascularization and less coloration than the BROWN FAT. White fat provides heat insulation, mechanical cushion, and source of energy.
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
Physiological processes in biosynthesis (anabolism) and degradation (catabolism) of LIPIDS.
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
Surgical procedure in which the STOMACH is transected high on the body. The resulting small proximal gastric pouch is joined to any parts of the SMALL INTESTINE by an end-to-side SURGICAL ANASTOMOSIS, depending on the amounts of intestinal surface being bypasses. This procedure is used frequently in the treatment of MORBID OBESITY by limiting the size of functional STOMACH, food intake, and food absorption.
Surgical procedures involving the STOMACH and sometimes the lower ESOPHAGUS to correct anatomical defects, or to treat MORBID OBESITY by reducing the size of the stomach. There are several subtypes of bariatric gastroplasty, such as vertical banded gastroplasty, silicone ring vertical gastroplasty, and horizontal banded gastroplasty.
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
Ventral part of the DIENCEPHALON extending from the region of the OPTIC CHIASM to the caudal border of the MAMMILLARY BODIES and forming the inferior and lateral walls of the THIRD VENTRICLE.
Concentrated pharmaceutical preparations of plants obtained by removing active constituents with a suitable solvent, which is evaporated away, and adjusting the residue to a prescribed standard.
Acquired or learned food preferences.
Elements of limited time intervals, contributing to particular results or situations.
Social and economic factors that characterize the individual or group within the social structure.
The distance from the sole to the crown of the head with body standing on a flat surface and fully extended.
Statistical models which describe the relationship between a qualitative dependent variable (that is, one which can take only certain discrete values, such as the presence or absence of a disease) and an independent variable. A common application is in epidemiology for estimating an individual's risk (probability of a disease) as a function of a given risk factor.
A low-energy attractive force between hydrogen and another element. It plays a major role in determining the properties of water, proteins, and other compounds.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
Physiologic mechanisms which regulate or control the appetite and food intake.
A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg).
Encouraging consumer behaviors most likely to optimize health potentials (physical and psychosocial) through health information, preventive programs, and access to medical care.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
The differentiation of pre-adipocytes into mature ADIPOCYTES.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
A systematic collection of factual data pertaining to health and disease in a human population within a given geographic area.
A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed)
Individuals whose ancestral origins are in the continent of Europe.
Antibodies produced by a single clone of cells.
A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms.
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
Pairing of purine and pyrimidine bases by HYDROGEN BONDING in double-stranded DNA or RNA.
The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases.
A diet designed to cause an individual to lose weight.
A plant genus of the family FABACEAE. Some Pachyrhizus have been reclassified to PUERARIA. Do not confuse with yam (IPOMOEA; or DIOSCOREA) or African yam bean (SPHENOSTYLIS).
Fatty tissue under the SKIN through out the body.
A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS.
Measurements of the height, weight, length, area, etc., of the human and animal body or its parts.
A nucleoside consisting of the base guanine and the sugar deoxyribose.
Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
Behaviors expressed by individuals to protect, maintain or promote their health status. For example, proper diet, and appropriate exercise are activities perceived to influence health status. Life style is closely associated with health behavior and factors influencing life style are socioeconomic, educational, and cultural.
The presence of co-existing or additional diseases with reference to an initial diagnosis or with reference to the index condition that is the subject of study. Comorbidity may affect the ability of affected individuals to function and also their survival; it may be used as a prognostic indicator for length of hospital stay, cost factors, and outcome or survival.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument.
An imbalanced NUTRITIONAL STATUS resulting from excessive intake of nutrients. Generally, overnutrition generates an energy imbalance between food consumption and energy expenditure leading to disorders such as OBESITY.
A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine).
A systematic collection of factual data pertaining to the nutritional status of a human population within a given geographic area. Data from these surveys are used in preparing NUTRITION ASSESSMENTS.
The generation of heat in order to maintain body temperature. The uncoupled oxidation of fatty acids contained within brown adipose tissue and SHIVERING are examples of thermogenesis in MAMMALS.
Studies in which variables relating to an individual or group of individuals are assessed over a period of time.
The measurement of subcutaneous fat located directly beneath the skin by grasping a fold of skin and subcutaneous fat between the thumb and forefinger and pulling it away from the underlying muscle tissue. The thickness of the double layer of skin and subcutaneous tissue is then read with a caliper. The five most frequently measured sites are the upper arm, below the scapula, above the hip bone, the abdomen, and the thigh. Its application is the determination of relative fatness, of changes in physical conditioning programs, and of the percentage of body fat in desirable body weight. (From McArdle, et al., Exercise Physiology, 2d ed, p496-8)
Agents that are used to suppress appetite.
Two populations of Zucker rats have been cited in research--the "fatty" or obese and the lean. The "fatty" rat (Rattus norvegicus) appeared as a spontaneous mutant. The obese condition appears to be due to a single recessive gene.
A secreted protein of approximately 131 amino acids (depending on species) that regulates the synthesis of eumelanin (brown/black) pigments in MELANOCYTES. Agouti protein antagonizes the signaling of MELANOCORTIN RECEPTORS and has wide distribution including ADIPOSE TISSUE; GONADS; and HEART. Its overexpression in agouti mice results in uniform yellow coat color, OBESITY, and metabolic defects similar to type II diabetes in humans.
A continuous cell line that is a substrain of SWISS 3T3 CELLS developed though clonal isolation. The mouse fibroblast cells undergo an adipose-like conversion as they move to a confluent and contact-inhibited state.
The number of males and females in a given population. The distribution may refer to how many men or women or what proportion of either in the group. The population is usually patients with a specific disease but the concept is not restricted to humans and is not restricted to medicine.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.
Cytosine nucleotides which contain deoxyribose as the sugar moiety.
Sucrose present in the diet. It is added to food and drinks as a sweetener.
A purine nucleoside that has guanine linked by its N9 nitrogen to the C1 carbon of ribose. It is a component of ribonucleic acid and its nucleotides play important roles in metabolism. (From Dorland, 28th ed)
The selection of one food over another.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
The transmission and reproduction of transient images of fixed or moving objects. An electronic system of transmitting such images together with sound over a wire or through space by apparatus that converts light and sound into electrical waves and reconverts them into visible light rays and audible sound. (From Webster, 3rd ed)
Deposits of ADIPOSE TISSUE throughout the body. The pattern of fat deposits in the body regions is an indicator of health status. Excess ABDOMINAL FAT increases health risks more than excess fat around the hips or thighs, therefore, WAIST-HIP RATIO is often used to determine health risks.
A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement.
Usual level of physical activity that is less than 30 minutes of moderate-intensity activity on most days of the week.
Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
The processes whereby the internal environment of an organism tends to remain balanced and stable.
Higher-order DNA and RNA structures formed from guanine-rich sequences. They are formed around a core of at least 2 stacked tetrads of hydrogen-bonded GUANINE bases. They can be formed from one two or four separate strands of DNA (or RNA) and can display a wide variety of topologies, which are a consequence of various combinations of strand direction, length, and sequence. (From Nucleic Acids Res. 2006;34(19):5402-15)
A latent susceptibility to disease at the genetic level, which may be activated under certain conditions.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
A thermogenic form of adipose tissue composed of BROWN ADIPOCYTES. It is found in newborns of many species including humans, and in hibernating mammals. Brown fat is richly vascularized, innervated, and densely packed with MITOCHONDRIA which can generate heat directly from the stored lipids.
Any substances taken in by the body that provide nourishment.
A 30-kDa protein synthesized primarily in the ANTERIOR PITUITARY GLAND and the HYPOTHALAMUS. It is also found in the skin and other peripheral tissues. Depending on species and tissues, POMC is cleaved by PROHORMONE CONVERTASES yielding various active peptides including ACTH; BETA-LIPOTROPIN; ENDORPHINS; MELANOCYTE-STIMULATING HORMONES; and others (GAMMA-LPH; CORTICOTROPIN-LIKE INTERMEDIATE LOBE PEPTIDE; N-terminal peptide of POMC or NPP).
The inhabitants of a city or town, including metropolitan areas and suburban areas.
The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS.
PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Statistical models in which the value of a parameter for a given value of a factor is assumed to be equal to a + bx, where a and b are constants. The models predict a linear regression.
A stratum of people with similar position and prestige; includes social stratification. Social class is measured by criteria such as education, occupation, and income.
Educational institutions.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
A single nucleotide variation in a genetic sequence that occurs at appreciable frequency in the population.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
Individuals whose ancestral origins are in the southeastern and eastern areas of the Asian continent.
Persons living in the United States of Mexican (MEXICAN AMERICANS), Puerto Rican, Cuban, Central or South American, or other Spanish culture or origin. The concept does not include Brazilian Americans or Portuguese Americans.
A group of deoxyribonucleotides (up to 12) in which the phosphate residues of each deoxyribonucleotide act as bridges in forming diester linkages between the deoxyribose moieties.
Adenine nucleotides which contain deoxyribose as the sugar moiety.
Inhaling and exhaling the smoke of burning TOBACCO.
Natural recurring desire for food. Alterations may be induced by APPETITE DEPRESSANTS or APPETITE STIMULANTS.
That portion of the body that lies between the THORAX and the PELVIS.
Use of plants or herbs to treat diseases or to alleviate pain.
Conditions with excess LIPIDS in the blood.
Persons living in the United States having origins in any of the black groups of Africa.
Behavioral response associated with the achieving of gratification.
Conditions or pathological processes associated with pregnancy. They can occur during or after pregnancy, and range from minor discomforts to serious diseases that require medical interventions. They include diseases in pregnant females, and pregnancies in females with diseases.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation.
Abstaining from all food.
A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose. It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules. (Dorland, 28th ed)
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
State of the body in relation to the consumption and utilization of nutrients.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Individuals whose ancestral origins are in the continent of Africa.
Nutritional physiology of children aged 2-12 years.
Reduction in caloric intake without reduction in adequate nutrition. In experimental animals, caloric restriction has been shown to extend lifespan and enhance other physiological variables.
7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno (3,4-b)oxirene-7,8-diol. A benzopyrene derivative with carcinogenic and mutagenic activity.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Nutrition of a mother which affects the health of the FETUS and INFANT as well as herself.
A purine base and a fundamental unit of ADENINE NUCLEOTIDES.
Plants whose roots, leaves, seeds, bark, or other constituent parts possess therapeutic, tonic, purgative, curative or other pharmacologic attributes, when administered to man or animals.
An autosomal recessive disorder characterized by RETINITIS PIGMENTOSA; POLYDACTYLY; OBESITY; MENTAL RETARDATION; hypogenitalism; renal dysplasia; and short stature. This syndrome has been distinguished as a separate entity from LAURENCE-MOON SYNDROME. (From J Med Genet 1997 Feb;34(2):92-8)
Carbohydrates present in food comprising digestible sugars and starches and indigestible cellulose and other dietary fibers. The former are the major source of energy. The sugars are in beet and cane sugar, fruits, honey, sweet corn, corn syrup, milk and milk products, etc.; the starches are in cereal grains, legumes (FABACEAE), tubers, etc. (From Claudio & Lagua, Nutrition and Diet Therapy Dictionary, 3d ed, p32, p277)
A 12-kDa cysteine-rich polypeptide hormone secreted by FAT CELLS in the ADIPOSE TISSUE. It is the founding member of the resistin-like molecule (RELM) hormone family. Resistin suppresses the ability of INSULIN to stimulate cellular GLUCOSE uptake.
A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable.
Educational attainment or level of education of individuals.
The frequency of different ages or age groups in a given population. The distribution may refer to either how many or what proportion of the group. The population is usually patients with a specific disease but the concept is not restricted to humans and is not restricted to medicine.
Persons functioning as natural, adoptive, or substitute parents. The heading includes the concept of parenthood as well as preparation for becoming a parent.
A country spanning from central Asia to the Pacific Ocean.
A species of thermoacidophilic ARCHAEA in the family Sulfolobaceae, found in volcanic areas where the temperature is about 80 degrees C and SULFUR is present.
The products of chemical reactions that result in the addition of extraneous chemical groups to DNA.
A subtype of striated muscle, attached by TENDONS to the SKELETON. Skeletal muscles are innervated and their movement can be consciously controlled. They are also called voluntary muscles.
The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality.
The consequences of exposing the FETUS in utero to certain factors, such as NUTRITION PHYSIOLOGICAL PHENOMENA; PHYSIOLOGICAL STRESS; DRUGS; RADIATION; and other physical or chemical factors. These consequences are observed later in the offspring after BIRTH.
The metabolic process of breaking down LIPIDS to release FREE FATTY ACIDS, the major oxidative fuel for the body. Lipolysis may involve dietary lipids in the DIGESTIVE TRACT, circulating lipids in the BLOOD, and stored lipids in the ADIPOSE TISSUE or the LIVER. A number of enzymes are involved in such lipid hydrolysis, such as LIPASE and LIPOPROTEIN LIPASE from various tissues.
The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.
Preventive health services provided for students. It excludes college or university students.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
The production and movement of food items from point of origin to use or consumption.
The physical measurements of a body.
Neoplastic, inflammatory, infectious, and other diseases of the hypothalamus. Clinical manifestations include appetite disorders; AUTONOMIC NERVOUS SYSTEM DISEASES; SLEEP DISORDERS; behavioral symptoms related to dysfunction of the LIMBIC SYSTEM; and neuroendocrine disorders.
A 28-amino acid, acylated, orexigenic peptide that is a ligand for GROWTH HORMONE SECRETAGOGUE RECEPTORS. Ghrelin is widely expressed but primarily in the stomach in the adults. Ghrelin acts centrally to stimulate growth hormone secretion and food intake, and peripherally to regulate energy homeostasis. Its large precursor protein, known as appetite-regulating hormone or motilin-related peptide, contains ghrelin and obestatin.
A surgical procedure which diverts pancreatobiliary secretions via the duodenum and the jejunum into the colon, the remaining small intestine being anastomosed to the stomach after antrectomy. The procedure produces less diarrhea than does jejunoileal bypass.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
Individual members of North American ethnic groups with ancient historic ancestral origins in Asia.

Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes--an update. (1/472)

Beta 3-adrenoceptor (beta 3-AR) agonists were found to have remarkable anti-obesity and anti-diabetic effects in rodents shortly after their discovery in the early 1980s. Despite these promising qualities, several pharmaceutical problems and theoretical concerns have slowed the development of these products as therapeutic agents in humans during the last 15 years. To date, the pharmaceutical industry has not been successful in developing a beta 3-AR agonist for use in the treatment of human obesity and type 2 diabetes. Pharmaceutical problems in this area concern important differences between rodent and human beta 3-AR and the difficulty in finding a compound with sufficient bioavailability that is a highly selective and full agonist at the human receptor. Some of these problems seem to have been solved with the cloning of the human beta 3-AR, which has made it possible to develop novel compounds directly and specifically against the human receptor. However, several theoretical concerns still remain. These include the major question as to whether the number of biologically active beta 3-ARs in adult humans is sufficient to produce relevant metabolic effects and, if so, whether their long-term stimulation is safe and free of unwarranted side effects. In addition, the mechanisms of action of beta 3-AR agonists remain poorly understood. Recent studies using CL 316,243, a highly selective beta 3-adrenergic compound, have provided new insights into the potential mechanisms of action of these drugs in rodents as well as the first evidence that treatment with a highly selective beta 3-AR agonist exerts relevant metabolic effects in humans. It appears that chronic beta 3-adrenergic stimulation in white adipose tissue increases the expression of newly discovered mitochondrial uncoupling proteins (UCP 2 and 3) and a "reawakening" of dormant brown adipocytes. In addition, beta 3-ARs may be present in skeletal muscle where ectopic expression of UCP-1 has been reported. If these findings are confirmed, tissues other than brown fat may play an important role in mediating beta 3-adrenergic effects on thermogenesis and substrate oxidation. In humans, treatment with CL 316,243 for 8 weeks, in spite of limited bioavailability, induced marked plasma concentration-dependent increases in insulin sensitivity, lipolysis, and fat oxidation in lean volunteers, without causing beta 1-, or beta 2-mediated side effects. These results clearly indicate that favourable metabolic effects can be achieved by selective beta 3-AR stimulation in humans. The compounds of the next generation currently emerging from preclinical development are full agonists at the human beta 3-AR. These agents have demonstrated promising results in non-human primates. It will be interesting to see whether their efficacy in clinical trials is superior to that achieved with previous (rodent) beta 3-AR agonists and, if so, whether their effects will eventually translate into weight loss and improved metabolic control that could facilitate their use as effective drugs for the treatment of obesity and Type 2 diabetes in humans.  (+info)

Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. (2/472)

BACKGROUND: Long-term maintenance of weight loss remains a therapeutic challenge in obesity treatment. OBJECTIVE: This multicenter, double-blind, placebo-controlled study was designed to test the hypothesis that orlistat, a gastrointestinal lipase inhibitor, is significantly more effective than a placebo in preventing weight regain. DESIGN: Obese subjects who lost > or = 8% of their initial body weight during a 6-mo lead-in of a prescribed hypoenergetic diet (4180-kJ/d deficit) with no adjunctive pharmacotherapy were randomly assigned to receive placebo, 30 mg orlistat, 60 mg orlistat, or 120 mg orlistat 3 times daily for 1 y in combination with a maintenance diet to help prevent weight regain. Of 1313 recruited subjects [body mass index (in kg/m2): 28-43], 729 subjects lost > or =8% of their initial body weight during the 6-mo weight-loss lead-in period and were enrolled in the double-blind phase. RESULTS: After 1 y, subjects treated with 120 mg orlistat 3 times daily regained less weight than did placebo-treated subjects (32.8 +/- 4.5% compared with 58.7 +/- 5.8% regain of lost weight; P < 0.001). Moreover, more subjects in the 120-mg orlistat group than in the placebo group regained < or = 25% of lost weight (47.5% of subjects compared with 29.9%). In addition, orlistat treatment (120 mg 3 times daily) was associated with significantly greater reductions in total and LDL-cholesterol concentrations than was placebo (P < 0.001). CONCLUSION: The use of orlistat during periods of attempted weight maintenance minimizes weight readjustment and facilitates long-term improvement in obesity-related disease risk factors.  (+info)

The effect of moxonidine on feeding and body fat in obese Zucker rats: role of hypothalamic NPY neurones. (3/472)

The antihypertensive agent moxonidine, an imidazoline Ii-receptor agonist, also induces hypophagia and lowers body weight in the obese spontaneously hypertensive rat, but the central mediation of this action and the neuronal pathways that moxonidine may interact with are not known. We studied whether moxonidine has anti-obesity effects in the genetically-obese and insulin-resistant fa/fa Zucker rat, and whether these are mediated through inhibition of the hypothalamic neuropeptide Y (NPY) neurones. Lean and obese Zucker rats were given moxonidine (3 mg kg(-1) day(-1)) or saline by gavage for 21 days. Moxonidine decreased food intake throughout by 20% in obese rats (P<0.001) and by 8% in lean rats (P<0.001), and reduced weight gain that final body weight was 15% lower in obese (P<0.001) and 7% lower in lean (P<0.01) rats than their untreated controls. Plasma insulin and leptin levels were decreased in moxonidine-treated obese rats (P<0.01 and P<0.05), but unchanged in treated lean rats. Uncoupling protein-1 gene expression in brown adipose tissue was stimulated by 40-50% (P< or =0.05) in both obese and lean animals given moxonidine. Obese animals given moxonidine showed a 37% reduction in hypothalamic NPY mRNA levels (P = 0.01), together with significantly increased NPY concentrations in the paraventricular nucleus (P<0.05), but no changes in the arcuate nucleus or other nuclei; this is consistent with reduced NPY synthesis in the arcuate nucleus and blocked release of NPY in the paraventricular nucleus. In lean animals, moxonidine did not affect NPY levels or NPY mRNA. The hypophagic, thermogenic and anti-obesity effects of moxonidine in obese Zucker rats may be partly due to inhibition of the NPY neurones, whose inappropriate overactivity may underlie obesity in this model.  (+info)

Review article: malnutrition and maltreatment--a comment on orlistat for the treatment of obesity. (4/472)

The prevalence of obesity has doubled in the last 10 years and is now reaching epidemic proportions. There is a significant comorbidity and financial cost associated with this disorder. Orlistat is an intestinal lipase inhibitor that is approved for the treatment of obesity. Recent randomized, double-blind, placebo-controlled trials have demonstrated the benefit of orlistat used in conjunction with a hypocaloric (low-fat) diet in facilitating weight reduction and the long-term maintenance of this weight loss. Patients treated with orlistat lost a greater amount of initial body weight compared to those who received placebo. After 24 months of treatment, weight loss of more than 5% was maintained in a greater number of those treated with orlistat. This was associated with significant reductions in cardiovascular risk factors (cholesterol, LDL cholesterol, LDL:HDL cholesterol ratio). The main adverse events are related to fat malabsorption, with potential losses of fat-soluble vitamins and other compounds. Orlistat as a treatment for obesity, when prescribed within present guidelines, can aid modest weight loss in about one-third of patients. More importantly, it can assist in the maintenance of weight loss with major medical benefits for these patients.  (+info)

Orlistat. No hurry.... (5/472)

Treatments for obesity are disappointing. None has yet shown an effect on morbidity and mortality. Nondrug treatments are poorly assessed. Stable long-term weight loss necessitates long-term management. Orlistat (Xenical, Hoffman-La Roche), a gastrointestinal lipase inhibitor, is indicated, in combination with a low-calorie diet, for management of obesity. The assessment file is bulky and methodologically sound, at least in terms of the weight loss end point. During medium-term trials (12 to 24 months), orlistat administered at a dose of 120 mg three times daily and combined with dietary intervention had a moderate positive effect on body weight (-3.5 kg on average). No longer-term trials have been done. It is unknown whether this drug affects morbidity and mortality linked to obesity. In clinical trials, patients treated with orlistat had an increased frequency of breast cancer. This potential risk is currently being assessed in a specific trial. Gastrointestinal adverse effects are frequent. Treatment is costly.  (+info)

Drug therapy for obesity. (6/472)

Obesity is a common health problem in the United States, and effective treatment is challenging. Obesity is associated with an increased mortality rate and risk factors such as hypertension, hyperlipidemia and diabetes mellitus. Numerous treatments are available for obesity. Behavioral therapy, surgery and pharmacologic treatment have been used with varying degrees of success. Older anorectic agents have significant side effects and limited benefit, and some have even been withdrawn from the U.S. market because of a possible association with cardiovascular complications. The safety of newer agents must be extensively evaluated before widespread use is recommended. Therefore, behavioral therapy, including regular exercise and the development of healthy eating habits, continues to be the best treatment for long-term weight loss.  (+info)

Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi) (7/472)

BACKGROUND: Chinese-herb nephropathy is a progressive form of renal fibrosis that develops in some patients who take weight-reducing pills containing Chinese herbs. Because of a manufacturing error, one of the herbs in these pills (Stephania tetrandra) was inadvertently replaced by Aristolochia fangchi, which is nephrotoxic and carcinogenic. METHODS: The diagnosis of a neoplastic lesion in the native urinary tract of a renal-transplant recipient who had Chinese-herb nephropathy prompted us to propose regular cystoscopic examinations and the prophylactic removal of the native kidneys and ureters in all our patients with end-stage Chinese-herb nephropathy who were being treated with either transplantation or dialysis. Surgical specimens were examined histologically and analyzed for the presence of DNA adducts formed by aristolochic acid. All prescriptions written for Chinese-herb weight-reducing compounds during the period of exposure (1990 to 1992) in these patients were obtained, and the cumulative doses were calculated. RESULTS: Among 39 patients who agreed to undergo prophylactic surgery, there were 18 cases of urothelial carcinoma (prevalence, 46 percent; 95 percent confidence interval, 29 to 62 percent): 17 cases of carcinoma of the ureter, renal pelvis, or both and 1 papillary bladder tumor. Nineteen of the remaining patients had mild-to-moderate urothelial dysplasia, and two had normal urothelium. All tissue samples analyzed contained aristolochic acid-related DNA adducts. The cumulative dose of aristolochia was a significant risk factor for urothelial carcinoma, with total doses of more than 200 g associated with a higher risk of urothelial carcinoma. CONCLUSIONS: The prevalence of urothelial carcinoma among patients with end-stage Chinese-herb nephropathy (caused by aristolochia species) is a high.  (+info)

Detection of impaired intestinal absorption of long-chain fatty acids: validation studies of a novel test in a rat model of fat malabsorption. (8/472)

BACKGROUND: Classic fat balance studies detect fat malabsorption but do not discriminate between the potential causes of malabsorption, such as impaired intestinal lipolysis or reduced uptake of fatty acids. OBJECTIVE: We aimed to validate a novel test for the specific, sensitive detection of impaired intestinal uptake of long-chain unesterified fatty acids in an appropriate rat model of fat malabsorption. DESIGN: The absorption and appearance in plasma of [(13)C]palmitic acid were determined in control rats and in rats with fat malabsorption due either to chronic bile deficiency (permanent bile diversion) or to oral administration of the lipase inhibitor orlistat (200 mg/kg diet). [(13)C]Palmitic acid results were compared with the percentage absorption of ingested dietary fat determined by fat balance. RESULTS: Between 1 and 6 h after intraduodenal administration, plasma [(13)C]palmitate concentrations in control rats were 4-10-fold higher than in bile-deficient rats (P < 0.05) but were not significantly different between orlistat-supplemented rats and their controls. In control and bile-deficient rats, plasma [(13)C]palmitate concentrations allowed complete discrimination between normal (>92%) and reduced (<92%) fat absorption, whereas the percentage absorption of [(13)C]palmitate over 48 h appeared to be highly correlated with the percentage absorption of ingested dietary fat (r = 0.89, P < 0.001). CONCLUSIONS: The [(13)C]palmitic acid absorption test detects impaired intestinal absorption of long-chain fatty acids selectively and sensitively in a rat model of fat malabsorption due to bile deficiency. Our data strongly support the use of the [(13)C]palmitic acid absorption test for the diagnosis of clinical fat malabsorption syndromes.  (+info)

There are several different types of obesity, including:

1. Central obesity: This type of obesity is characterized by excess fat around the waistline, which can increase the risk of health problems such as type 2 diabetes and cardiovascular disease.
2. Peripheral obesity: This type of obesity is characterized by excess fat in the hips, thighs, and arms.
3. Visceral obesity: This type of obesity is characterized by excess fat around the internal organs in the abdominal cavity.
4. Mixed obesity: This type of obesity is characterized by both central and peripheral obesity.

Obesity can be caused by a variety of factors, including genetics, lack of physical activity, poor diet, sleep deprivation, and certain medications. Treatment for obesity typically involves a combination of lifestyle changes, such as increased physical activity and a healthy diet, and in some cases, medication or surgery may be necessary to achieve weight loss.

Preventing obesity is important for overall health and well-being, and can be achieved through a variety of strategies, including:

1. Eating a healthy, balanced diet that is low in added sugars, saturated fats, and refined carbohydrates.
2. Engaging in regular physical activity, such as walking, jogging, or swimming.
3. Getting enough sleep each night.
4. Managing stress levels through relaxation techniques, such as meditation or deep breathing.
5. Avoiding excessive alcohol consumption and quitting smoking.
6. Monitoring weight and body mass index (BMI) on a regular basis to identify any changes or potential health risks.
7. Seeking professional help from a healthcare provider or registered dietitian for personalized guidance on weight management and healthy lifestyle choices.

Morbid obesity is typically defined as a BMI of 40 or higher, but some experts define it as a BMI of 35 or higher with one or more obesity-related health conditions, such as high blood pressure, type 2 diabetes, or sleep apnea.

Morbid obesity is different from simple obesity, which is defined as a BMI of 30 to 39. While simple obesity can also increase the risk of health problems, it is generally considered less severe than morbid obesity.

Morbid obesity is often treated with a combination of lifestyle changes, such as diet and exercise, and medications or surgery. In some cases, bariatric surgery may be recommended to help achieve and maintain weight loss.

It is important to note that BMI is not always an accurate measure of health, as it does not take into account muscle mass or body composition. However, it can provide a general indicator of whether an individual is at a healthy weight or if they are at risk for health problems due to their weight.

There are several ways to measure abdominal obesity, including:

1. Waist circumference: Measured by circling the natural waistline with a tape measure. Excess fat around the waistline is defined as a circumference of 35 inches or more for women and 40 inches or more for men.
2. Waist-to-hip ratio: Measured by dividing the circumference of the natural waistline by the circumference of the hips. A ratio of 0.8 or higher indicates abdominal obesity.
3. Body fat distribution: Measured using techniques such as dual-energy X-ray absorptiometry (DXA) or bioelectrical impedance analysis (BIA). These methods can estimate the amount of fat in various areas of the body, including the abdomen.

There are several factors that contribute to the development of abdominal obesity, including:

1. Genetics: Inheritance plays a role in the distribution of body fat, with some people more prone to accumulating fat around the midsection.
2. Poor diet: Consuming high amounts of processed foods, sugar, and saturated fats can contribute to weight gain and abdominal obesity.
3. Lack of physical activity: Sedentary lifestyle can lead to a decrease in muscle mass and an increase in body fat, including around the abdomen.
4. Age: As people age, their metabolism slows down, leading to weight gain and increased risk of obesity.
5. Hormonal imbalances: Certain hormonal imbalances, such as hypothyroidism or polycystic ovary syndrome (PCOS), can increase the risk of developing abdominal obesity.

Abdominal obesity is a significant health risk due to its association with various chronic diseases, including:

1. Type 2 diabetes: Excess fat around the abdominal area can lead to insulin resistance and increase the risk of developing type 2 diabetes.
2. Cardiovascular disease: Abdominal obesity is a major risk factor for heart disease, as excess fat in this area can increase the risk of high blood pressure, high cholesterol, and triglycerides.
3. Cancer: Studies have shown that central obesity is associated with an increased risk of certain types of cancer, including colon, breast, and pancreatic cancer.
4. Non-alcoholic fatty liver disease (NAFLD): Abdominal obesity can lead to the development of NAFLD, a condition characterized by fat accumulation in the liver, which can increase the risk of liver damage and other health complications.
5. Sleep apnea: Excess fat around the abdomen can increase the risk of sleep apnea, a condition characterized by pauses in breathing during sleep.
6. Respiratory problems: Abdominal obesity can increase the risk of respiratory problems, such as asthma and chronic obstructive pulmonary disease (COPD).
7. Osteoarthritis: Excess weight, particularly around the abdomen, can increase the risk of osteoarthritis in the knees and hips.
8. Mental health: Central obesity has been linked to an increased risk of depression and other mental health conditions.
9. Fertility problems: Abdominal obesity can affect fertility in both men and women, as excess fat can disrupt hormone levels and reduce the likelihood of conception.
10. Reduced life expectancy: Abdominal obesity is associated with a shorter life expectancy, as it increases the risk of various chronic diseases that can reduce lifespan.

Pediatric obesity can be caused by a combination of genetic, environmental, and lifestyle factors, including:

1. Genetics: A family history of obesity can increase the risk of pediatric obesity.
2. Poor diet: Consuming high-calorie foods and drinks that are high in sugar, fat, and salt can contribute to weight gain.
3. Lack of physical activity: Sedentary behavior, such as watching television or playing video games, can lead to weight gain.
4. Sleep deprivation: Not getting enough sleep can disrupt hormones that regulate appetite and metabolism, leading to weight gain.
5. Socioeconomic factors: Families with lower socioeconomic status may have limited access to healthy food options and safe places for physical activity.

The diagnosis of pediatric obesity is based on BMI-for-age growth charts, which are age- and gender-specific growth charts that take into account the normal range of weight and height for children and adolescents. Treatment for pediatric obesity typically involves a combination of lifestyle modifications, such as healthy eating habits and regular physical activity, and in some cases, medication or surgery may be necessary.

Preventing pediatric obesity is important, and it starts with promoting healthy habits in early childhood. Parents can encourage their children to eat a balanced diet, limit screen time, and engage in regular physical activity. Healthcare providers can also play a crucial role in identifying and addressing risk factors for pediatric obesity, such as poor eating habits and lack of physical activity. By working together with families and communities, we can help prevent pediatric obesity and promote the healthy development of our children.

Being overweight can increase the risk of various health problems, such as heart disease, type 2 diabetes, high blood pressure, and certain types of cancer. It can also affect a person's mental health and overall quality of life.

There are several ways to assess whether someone is overweight or not. One common method is using the BMI, which is calculated based on height and weight. Another method is measuring body fat percentage, which can be done with specialized tools such as skinfold calipers or bioelectrical impedance analysis (BIA).

Losing weight and maintaining a healthy weight can be achieved through a combination of diet, exercise, and lifestyle changes. Some examples of healthy weight loss strategies include:

* Eating a balanced diet that is high in fruits, vegetables, whole grains, and lean protein sources
* Engaging in regular physical activity, such as walking, running, swimming, or weight training
* Avoiding fad diets and quick fixes
* Getting enough sleep and managing stress levels
* Setting realistic weight loss goals and tracking progress over time.

Body weight is an important health indicator, as it can affect an individual's risk for certain medical conditions, such as obesity, diabetes, and cardiovascular disease. Maintaining a healthy body weight is essential for overall health and well-being, and there are many ways to do so, including a balanced diet, regular exercise, and other lifestyle changes.

There are several ways to measure body weight, including:

1. Scale: This is the most common method of measuring body weight, and it involves standing on a scale that displays the individual's weight in kg or lb.
2. Body fat calipers: These are used to measure body fat percentage by pinching the skin at specific points on the body.
3. Skinfold measurements: This method involves measuring the thickness of the skin folds at specific points on the body to estimate body fat percentage.
4. Bioelectrical impedance analysis (BIA): This is a non-invasive method that uses electrical impulses to measure body fat percentage.
5. Dual-energy X-ray absorptiometry (DXA): This is a more accurate method of measuring body composition, including bone density and body fat percentage.

It's important to note that body weight can fluctuate throughout the day due to factors such as water retention, so it's best to measure body weight at the same time each day for the most accurate results. Additionally, it's important to use a reliable scale or measuring tool to ensure accurate measurements.

There are several factors that can contribute to the development of insulin resistance, including:

1. Genetics: Insulin resistance can be inherited, and some people may be more prone to developing the condition based on their genetic makeup.
2. Obesity: Excess body fat, particularly around the abdominal area, can contribute to insulin resistance.
3. Physical inactivity: A sedentary lifestyle can lead to insulin resistance.
4. Poor diet: Consuming a diet high in refined carbohydrates and sugar can contribute to insulin resistance.
5. Other medical conditions: Certain medical conditions, such as polycystic ovary syndrome (PCOS) and Cushing's syndrome, can increase the risk of developing insulin resistance.
6. Medications: Certain medications, such as steroids and some antipsychotic drugs, can increase insulin resistance.
7. Hormonal imbalances: Hormonal changes during pregnancy or menopause can lead to insulin resistance.
8. Sleep apnea: Sleep apnea can contribute to insulin resistance.
9. Chronic stress: Chronic stress can lead to insulin resistance.
10. Aging: Insulin resistance tends to increase with age, particularly after the age of 45.

There are several ways to diagnose insulin resistance, including:

1. Fasting blood sugar test: This test measures the level of glucose in the blood after an overnight fast.
2. Glucose tolerance test: This test measures the body's ability to regulate blood sugar levels after consuming a sugary drink.
3. Insulin sensitivity test: This test measures the body's ability to respond to insulin.
4. Homeostatic model assessment (HOMA): This is a mathematical formula that uses the results of a fasting glucose and insulin test to estimate insulin resistance.
5. Adiponectin test: This test measures the level of adiponectin, a protein produced by fat cells that helps regulate blood sugar levels. Low levels of adiponectin are associated with insulin resistance.

There is no cure for insulin resistance, but it can be managed through lifestyle changes and medication. Lifestyle changes include:

1. Diet: A healthy diet that is low in processed carbohydrates and added sugars can help improve insulin sensitivity.
2. Exercise: Regular physical activity, such as aerobic exercise and strength training, can improve insulin sensitivity.
3. Weight loss: Losing weight, particularly around the abdominal area, can improve insulin sensitivity.
4. Stress management: Strategies to manage stress, such as meditation or yoga, can help improve insulin sensitivity.
5. Sleep: Getting adequate sleep is important for maintaining healthy insulin levels.

Medications that may be used to treat insulin resistance include:

1. Metformin: This is a commonly used medication to treat type 2 diabetes and improve insulin sensitivity.
2. Thiazolidinediones (TZDs): These medications, such as pioglitazone, improve insulin sensitivity by increasing the body's ability to use insulin.
3. Sulfonylureas: These medications stimulate the release of insulin from the pancreas, which can help improve insulin sensitivity.
4. DPP-4 inhibitors: These medications, such as sitagliptin, work by reducing the breakdown of the hormone incretin, which helps to increase insulin secretion and improve insulin sensitivity.
5. GLP-1 receptor agonists: These medications, such as exenatide, mimic the action of the hormone GLP-1 and help to improve insulin sensitivity.

It is important to note that these medications may have side effects, so it is important to discuss the potential benefits and risks with your healthcare provider before starting treatment. Additionally, lifestyle modifications such as diet and exercise can also be effective in improving insulin sensitivity and managing blood sugar levels.

There are many different approaches to weight loss, and what works best for one person may not work for another. Some common strategies for weight loss include:

* Caloric restriction: Reducing daily caloric intake to create a calorie deficit that promotes weight loss.
* Portion control: Eating smaller amounts of food and avoiding overeating.
* Increased physical activity: Engaging in regular exercise, such as walking, running, swimming, or weightlifting, to burn more calories and build muscle mass.
* Behavioral modifications: Changing habits and behaviors related to eating and exercise, such as keeping a food diary or enlisting the support of a weight loss buddy.

Weight loss can have numerous health benefits, including:

* Improved blood sugar control
* Reduced risk of heart disease and stroke
* Lowered blood pressure
* Improved joint health and reduced risk of osteoarthritis
* Improved sleep quality
* Boosted mood and reduced stress levels
* Increased energy levels

However, weight loss can also be challenging, and it is important to approach it in a healthy and sustainable way. Crash diets and other extreme weight loss methods are not effective in the long term and can lead to nutrient deficiencies and other negative health consequences. Instead, it is important to focus on making sustainable lifestyle changes that can be maintained over time.

Some common misconceptions about weight loss include:

* All weight loss methods are effective for everyone.
* Weight loss should always be the primary goal of a fitness or health program.
* Crash diets and other extreme weight loss methods are a good way to lose weight quickly.
* Weight loss supplements and fad diets are a reliable way to achieve significant weight loss.

The most effective ways to lose weight and maintain weight loss include:

* Eating a healthy, balanced diet that is high in nutrient-dense foods such as fruits, vegetables, whole grains, lean proteins, and healthy fats.
* Engaging in regular physical activity, such as walking, running, swimming, or weight training.
* Getting enough sleep and managing stress levels.
* Aiming for a gradual weight loss of 1-2 pounds per week.
* Focusing on overall health and wellness rather than just the number on the scale.

It is important to remember that weight loss is not always linear and can vary from week to week. It is also important to be patient and consistent with your weight loss efforts, as it can take time to see significant results.

Overall, weight loss can be a challenging but rewarding process, and it is important to approach it in a healthy and sustainable way. By focusing on overall health and wellness rather than just the number on the scale, you can achieve a healthy weight and improve your overall quality of life.

There are several different types of weight gain, including:

1. Clinical obesity: This is defined as a BMI of 30 or higher, and is typically associated with a range of serious health problems, such as heart disease, type 2 diabetes, and certain types of cancer.
2. Central obesity: This refers to excess fat around the waistline, which can increase the risk of health problems such as heart disease and type 2 diabetes.
3. Muscle gain: This occurs when an individual gains weight due to an increase in muscle mass, rather than fat. This type of weight gain is generally considered healthy and can improve overall fitness and athletic performance.
4. Fat gain: This occurs when an individual gains weight due to an increase in body fat, rather than muscle or bone density. Fat gain can increase the risk of health problems such as heart disease and type 2 diabetes.

Weight gain can be measured using a variety of methods, including:

1. Body mass index (BMI): This is a widely used measure of weight gain that compares an individual's weight to their height. A BMI of 18.5-24.9 is considered normal, while a BMI of 25-29.9 is considered overweight, and a BMI of 30 or higher is considered obese.
2. Waist circumference: This measures the distance around an individual's waistline and can be used to assess central obesity.
3. Skinfold measurements: These involve measuring the thickness of fat at specific points on the body, such as the abdomen or thighs.
4. Dual-energy X-ray absorptiometry (DXA): This is a non-invasive test that uses X-rays to measure bone density and body composition.
5. Bioelectrical impedance analysis (BIA): This is a non-invasive test that uses electrical impulses to measure body fat percentage and other physiological parameters.

Causes of weight gain:

1. Poor diet: Consuming high amounts of processed foods, sugar, and saturated fats can lead to weight gain.
2. Lack of physical activity: Engaging in regular exercise can help burn calories and maintain a healthy weight.
3. Genetics: An individual's genetic makeup can affect their metabolism and body composition, making them more prone to weight gain.
4. Hormonal imbalances: Imbalances in hormones such as insulin, thyroid, and cortisol can contribute to weight gain.
5. Medications: Certain medications, such as steroids and antidepressants, can cause weight gain as a side effect.
6. Sleep deprivation: Lack of sleep can disrupt hormones that regulate appetite and metabolism, leading to weight gain.
7. Stress: Chronic stress can lead to emotional eating and weight gain.
8. Age: Metabolism slows down with age, making it more difficult to maintain a healthy weight.
9. Medical conditions: Certain medical conditions such as hypothyroidism, Cushing's syndrome, and polycystic ovary syndrome (PCOS) can also contribute to weight gain.

Treatment options for obesity:

1. Lifestyle modifications: A combination of diet, exercise, and stress management techniques can help individuals achieve and maintain a healthy weight.
2. Medications: Prescription medications such as orlistat, phentermine-topiramate, and liraglutide can aid in weight loss.
3. Bariatric surgery: Surgical procedures such as gastric bypass surgery and sleeve gastrectomy can be effective for severe obesity.
4. Behavioral therapy: Cognitive-behavioral therapy (CBT) and other forms of counseling can help individuals develop healthy eating habits and improve their physical activity levels.
5. Meal replacement plans: Meal replacement plans such as Medifast can provide individuals with a structured diet that is high in protein, fiber, and vitamins, and low in calories and sugar.
6. Weight loss supplements: Supplements such as green tea extract, garcinia cambogia, and forskolin can help boost weight loss efforts.
7. Portion control: Using smaller plates and measuring cups can help individuals regulate their portion sizes and maintain a healthy weight.
8. Mindful eating: Paying attention to hunger and fullness cues, eating slowly, and savoring food can help individuals develop healthy eating habits.
9. Physical activity: Engaging in regular physical activity such as walking, running, swimming, or cycling can help individuals burn calories and maintain a healthy weight.

It's important to note that there is no one-size-fits-all approach to treating obesity, and the most effective treatment plan will depend on the individual's specific needs and circumstances. Consulting with a healthcare professional such as a registered dietitian or a physician can help individuals develop a personalized treatment plan that is safe and effective.

1. Abdominal obesity (excess fat around the waistline)
2. High blood pressure (hypertension)
3. Elevated fasting glucose (high blood sugar)
4. High serum triglycerides (elevated levels of triglycerides in the blood)
5. Low HDL cholesterol (low levels of "good" cholesterol)

Having three or more of these conditions is considered a diagnosis of metabolic syndrome X. It is estimated that approximately 34% of adults in the United States have this syndrome, and it is more common in women than men. Risk factors for developing metabolic syndrome include obesity, lack of physical activity, poor diet, and a family history of type 2 diabetes or CVD.

The term "metabolic syndrome" was first introduced in the medical literature in the late 1980s, and since then, it has been the subject of extensive research. The exact causes of metabolic syndrome are not yet fully understood, but it is believed to be related to insulin resistance, inflammation, and changes in body fat distribution.

Treatment for metabolic syndrome typically involves lifestyle modifications such as weight loss, regular physical activity, and a healthy diet. Medications such as blood pressure-lowering drugs, cholesterol-lowering drugs, and anti-diabetic medications may also be prescribed if necessary. It is important to note that not everyone with metabolic syndrome will develop type 2 diabetes or CVD, but the risk is increased. Therefore, early detection and treatment are crucial in preventing these complications.

Type 2 diabetes can be managed through a combination of diet, exercise, and medication. In some cases, lifestyle changes may be enough to control blood sugar levels, while in other cases, medication or insulin therapy may be necessary. Regular monitoring of blood sugar levels and follow-up with a healthcare provider are important for managing the condition and preventing complications.

Common symptoms of type 2 diabetes include:

* Increased thirst and urination
* Fatigue
* Blurred vision
* Cuts or bruises that are slow to heal
* Tingling or numbness in the hands and feet
* Recurring skin, gum, or bladder infections

If left untreated, type 2 diabetes can lead to a range of complications, including:

* Heart disease and stroke
* Kidney damage and failure
* Nerve damage and pain
* Eye damage and blindness
* Foot damage and amputation

The exact cause of type 2 diabetes is not known, but it is believed to be linked to a combination of genetic and lifestyle factors, such as:

* Obesity and excess body weight
* Lack of physical activity
* Poor diet and nutrition
* Age and family history
* Certain ethnicities (e.g., African American, Hispanic/Latino, Native American)
* History of gestational diabetes or delivering a baby over 9 lbs.

There is no cure for type 2 diabetes, but it can be managed and controlled through a combination of lifestyle changes and medication. With proper treatment and self-care, people with type 2 diabetes can lead long, healthy lives.

In medicine, thinness is sometimes used as a diagnostic criterion for certain conditions, such as anorexia nervosa or cancer cachexia. In these cases, thinness can be a sign of a serious underlying condition that requires medical attention.

However, it's important to note that thinness alone is not enough to diagnose any medical condition. Other factors, such as a person's overall health, medical history, and physical examination findings, must also be taken into account when making a diagnosis. Additionally, it's important to recognize that being underweight or having a low BMI does not necessarily mean that someone is unhealthy or has a medical condition. Many people with a healthy weight and body composition can still experience negative health effects from societal pressure to be thin.

Overall, the concept of thinness in medicine is complex and multifaceted, and it's important for healthcare providers to consider all relevant factors when evaluating a patient's weight and overall health.

People with OHS often experience symptoms such as shortness of breath, fatigue, and difficulty sleeping due to lack of oxygen. In severe cases, OHS can lead to respiratory failure, heart failure, and other complications.

Treatment for OHS typically involves weight loss through diet and exercise, as well as mechanical ventilation assistance at night to help improve breathing. Bariatric surgery may also be recommended in some cases. It is important for individuals with OHS to work closely with their healthcare provider to manage their condition and prevent complications.

Definition: Hyperphagia is a condition characterized by excessive hunger and overeating, often seen in individuals with certain medical or psychiatric conditions.

More Information

Hyperphagia can be caused by a variety of factors, including:

* Hormonal imbalances, such as low levels of leptin or high levels of ghrelin
* Certain medications, such as steroids and some antidepressants
* Medical conditions, such as diabetes, hypothyroidism, and polycystic ovary syndrome (PCOS)
* Psychiatric conditions, such as binge eating disorder and other eating disorders
* Sleep deprivation or disruptions in the body's circadian rhythms

Symptoms of hyperphagia may include:

* Increased hunger and desire to eat
* Overeating or consuming large amounts of food
* Difficulty controlling food intake
* Feeling anxious or irritable when unable to eat
* Weight gain or obesity

Treatment for hyperphagia typically involves addressing the underlying cause, such as hormonal imbalances or psychiatric conditions. This may involve medication, therapy, or lifestyle changes. In some cases, weight loss strategies and nutrition counseling may also be helpful.

It is important to note that hyperphagia can have serious health consequences, including obesity, type 2 diabetes, and other metabolic disorders. If you suspect you or someone you know may be experiencing hyperphagia, it is important to seek medical attention to determine the cause and develop an appropriate treatment plan.

These diseases can cause a wide range of symptoms such as fatigue, weight changes, and poor wound healing. Treatment options vary depending on the specific condition but may include lifestyle changes, medications, or surgery.

There are several types of diabetes mellitus, including:

1. Type 1 DM: This is an autoimmune condition in which the body's immune system attacks and destroys the cells in the pancreas that produce insulin, resulting in a complete deficiency of insulin production. It typically develops in childhood or adolescence, and patients with this condition require lifelong insulin therapy.
2. Type 2 DM: This is the most common form of diabetes, accounting for around 90% of all cases. It is caused by a combination of insulin resistance (where the body's cells do not respond properly to insulin) and impaired insulin secretion. It is often associated with obesity, physical inactivity, and a diet high in sugar and unhealthy fats.
3. Gestational DM: This type of diabetes develops during pregnancy, usually in the second or third trimester. Hormonal changes and insulin resistance can cause blood sugar levels to rise, putting both the mother and baby at risk.
4. LADA (Latent Autoimmune Diabetes in Adults): This is a form of type 1 DM that develops in adults, typically after the age of 30. It shares features with both type 1 and type 2 DM.
5. MODY (Maturity-Onset Diabetes of the Young): This is a rare form of diabetes caused by genetic mutations that affect insulin production. It typically develops in young adulthood and can be managed with lifestyle changes and/or medication.

The symptoms of diabetes mellitus can vary depending on the severity of the condition, but may include:

1. Increased thirst and urination
2. Fatigue
3. Blurred vision
4. Cuts or bruises that are slow to heal
5. Tingling or numbness in hands and feet
6. Recurring skin, gum, or bladder infections
7. Flu-like symptoms such as weakness, dizziness, and stomach pain
8. Dark, velvety skin patches (acanthosis nigricans)
9. Yellowish color of the skin and eyes (jaundice)
10. Delayed healing of cuts and wounds

If left untreated, diabetes mellitus can lead to a range of complications, including:

1. Heart disease and stroke
2. Kidney damage and failure
3. Nerve damage (neuropathy)
4. Eye damage (retinopathy)
5. Foot damage (neuropathic ulcers)
6. Cognitive impairment and dementia
7. Increased risk of infections and other diseases, such as pneumonia, gum disease, and urinary tract infections.

It is important to note that not all individuals with diabetes will experience these complications, and that proper management of the condition can greatly reduce the risk of developing these complications.

There are two main types of fatty liver disease:

1. Alcoholic fatty liver disease (AFLD): This type of fatty liver disease is caused by excessive alcohol consumption and is the most common cause of fatty liver disease in the United States.
2. Non-alcoholic fatty liver disease (NAFLD): This type of fatty liver disease is not caused by alcohol consumption and is the most common cause of fatty liver disease worldwide. It is often associated with obesity, diabetes, and high cholesterol.

There are several risk factors for developing fatty liver disease, including:

* Obesity
* Physical inactivity
* High calorie intake
* Alcohol consumption
* Diabetes
* High cholesterol
* High triglycerides
* History of liver disease

Symptoms of fatty liver disease can include:

* Fatigue
* Abdominal discomfort
* Loss of appetite
* Nausea and vomiting
* Abnormal liver function tests

Diagnosis of fatty liver disease is typically made through a combination of physical examination, medical history, and diagnostic tests such as:

* Liver biopsy
* Imaging studies (ultrasound, CT or MRI scans)
* Blood tests (lipid profile, glucose, insulin, and liver function tests)

Treatment of fatty liver disease depends on the underlying cause and severity of the condition. Lifestyle modifications such as weight loss, exercise, and a healthy diet can help improve the condition. In severe cases, medications such as antioxidants, fibric acids, and anti-inflammatory drugs may be prescribed. In some cases, surgery or other procedures may be necessary.

Prevention of fatty liver disease includes:

* Maintaining a healthy weight
* Eating a balanced diet low in sugar and saturated fats
* Engaging in regular physical activity
* Limiting alcohol consumption
* Managing underlying medical conditions such as diabetes and high cholesterol.

1. Coronary artery disease: The narrowing or blockage of the coronary arteries, which supply blood to the heart.
2. Heart failure: A condition in which the heart is unable to pump enough blood to meet the body's needs.
3. Arrhythmias: Abnormal heart rhythms that can be too fast, too slow, or irregular.
4. Heart valve disease: Problems with the heart valves that control blood flow through the heart.
5. Heart muscle disease (cardiomyopathy): Disease of the heart muscle that can lead to heart failure.
6. Congenital heart disease: Defects in the heart's structure and function that are present at birth.
7. Peripheral artery disease: The narrowing or blockage of blood vessels that supply oxygen and nutrients to the arms, legs, and other organs.
8. Deep vein thrombosis (DVT): A blood clot that forms in a deep vein, usually in the leg.
9. Pulmonary embolism: A blockage in one of the arteries in the lungs, which can be caused by a blood clot or other debris.
10. Stroke: A condition in which there is a lack of oxygen to the brain due to a blockage or rupture of blood vessels.

There are two types of hypertension:

1. Primary Hypertension: This type of hypertension has no identifiable cause and is also known as essential hypertension. It accounts for about 90% of all cases of hypertension.
2. Secondary Hypertension: This type of hypertension is caused by an underlying medical condition or medication. It accounts for about 10% of all cases of hypertension.

Some common causes of secondary hypertension include:

* Kidney disease
* Adrenal gland disorders
* Hormonal imbalances
* Certain medications
* Sleep apnea
* Cocaine use

There are also several risk factors for hypertension, including:

* Age (the risk increases with age)
* Family history of hypertension
* Obesity
* Lack of exercise
* High sodium intake
* Low potassium intake
* Stress

Hypertension is often asymptomatic, and it can cause damage to the blood vessels and organs over time. Some potential complications of hypertension include:

* Heart disease (e.g., heart attacks, heart failure)
* Stroke
* Kidney disease (e.g., chronic kidney disease, end-stage renal disease)
* Vision loss (e.g., retinopathy)
* Peripheral artery disease

Hypertension is typically diagnosed through blood pressure readings taken over a period of time. Treatment for hypertension may include lifestyle changes (e.g., diet, exercise, stress management), medications, or a combination of both. The goal of treatment is to reduce the risk of complications and improve quality of life.

1) They share similarities with humans: Many animal species share similar biological and physiological characteristics with humans, making them useful for studying human diseases. For example, mice and rats are often used to study diseases such as diabetes, heart disease, and cancer because they have similar metabolic and cardiovascular systems to humans.

2) They can be genetically manipulated: Animal disease models can be genetically engineered to develop specific diseases or to model human genetic disorders. This allows researchers to study the progression of the disease and test potential treatments in a controlled environment.

3) They can be used to test drugs and therapies: Before new drugs or therapies are tested in humans, they are often first tested in animal models of disease. This allows researchers to assess the safety and efficacy of the treatment before moving on to human clinical trials.

4) They can provide insights into disease mechanisms: Studying disease models in animals can provide valuable insights into the underlying mechanisms of a particular disease. This information can then be used to develop new treatments or improve existing ones.

5) Reduces the need for human testing: Using animal disease models reduces the need for human testing, which can be time-consuming, expensive, and ethically challenging. However, it is important to note that animal models are not perfect substitutes for human subjects, and results obtained from animal studies may not always translate to humans.

6) They can be used to study infectious diseases: Animal disease models can be used to study infectious diseases such as HIV, TB, and malaria. These models allow researchers to understand how the disease is transmitted, how it progresses, and how it responds to treatment.

7) They can be used to study complex diseases: Animal disease models can be used to study complex diseases such as cancer, diabetes, and heart disease. These models allow researchers to understand the underlying mechanisms of the disease and test potential treatments.

8) They are cost-effective: Animal disease models are often less expensive than human clinical trials, making them a cost-effective way to conduct research.

9) They can be used to study drug delivery: Animal disease models can be used to study drug delivery and pharmacokinetics, which is important for developing new drugs and drug delivery systems.

10) They can be used to study aging: Animal disease models can be used to study the aging process and age-related diseases such as Alzheimer's and Parkinson's. This allows researchers to understand how aging contributes to disease and develop potential treatments.

There are several key features of inflammation:

1. Increased blood flow: Blood vessels in the affected area dilate, allowing more blood to flow into the tissue and bringing with it immune cells, nutrients, and other signaling molecules.
2. Leukocyte migration: White blood cells, such as neutrophils and monocytes, migrate towards the site of inflammation in response to chemical signals.
3. Release of mediators: Inflammatory mediators, such as cytokines and chemokines, are released by immune cells and other cells in the affected tissue. These molecules help to coordinate the immune response and attract more immune cells to the site of inflammation.
4. Activation of immune cells: Immune cells, such as macrophages and T cells, become activated and start to phagocytose (engulf) pathogens or damaged tissue.
5. Increased heat production: Inflammation can cause an increase in metabolic activity in the affected tissue, leading to increased heat production.
6. Redness and swelling: Increased blood flow and leakiness of blood vessels can cause redness and swelling in the affected area.
7. Pain: Inflammation can cause pain through the activation of nociceptors (pain-sensing neurons) and the release of pro-inflammatory mediators.

Inflammation can be acute or chronic. Acute inflammation is a short-term response to injury or infection, which helps to resolve the issue quickly. Chronic inflammation is a long-term response that can cause ongoing damage and diseases such as arthritis, asthma, and cancer.

There are several types of inflammation, including:

1. Acute inflammation: A short-term response to injury or infection.
2. Chronic inflammation: A long-term response that can cause ongoing damage and diseases.
3. Autoimmune inflammation: An inappropriate immune response against the body's own tissues.
4. Allergic inflammation: An immune response to a harmless substance, such as pollen or dust mites.
5. Parasitic inflammation: An immune response to parasites, such as worms or fungi.
6. Bacterial inflammation: An immune response to bacteria.
7. Viral inflammation: An immune response to viruses.
8. Fungal inflammation: An immune response to fungi.

There are several ways to reduce inflammation, including:

1. Medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying anti-rheumatic drugs (DMARDs).
2. Lifestyle changes, such as a healthy diet, regular exercise, stress management, and getting enough sleep.
3. Alternative therapies, such as acupuncture, herbal supplements, and mind-body practices.
4. Addressing underlying conditions, such as hormonal imbalances, gut health issues, and chronic infections.
5. Using anti-inflammatory compounds found in certain foods, such as omega-3 fatty acids, turmeric, and ginger.

It's important to note that chronic inflammation can lead to a range of health problems, including:

1. Arthritis
2. Diabetes
3. Heart disease
4. Cancer
5. Alzheimer's disease
6. Parkinson's disease
7. Autoimmune disorders, such as lupus and rheumatoid arthritis.

Therefore, it's important to manage inflammation effectively to prevent these complications and improve overall health and well-being.

In hyperinsulinism, the body produces too much insulin, leading to a range of symptoms including:

1. Hypoglycemia (low blood sugar): Excessive insulin can cause blood sugar levels to drop too low, leading to hypoglycemic symptoms such as shakiness, dizziness, confusion, and rapid heartbeat.
2. Weight gain: Hyperinsulinism can lead to weight gain due to the body's inability to effectively use glucose for energy production.
3. Fatigue: Excessive insulin can cause fatigue, as the body's cells are not able to effectively use glucose for energy production.
4. Mood changes: Hyperinsulinism can lead to mood changes such as irritability, anxiety, and depression.
5. Polycystic ovary syndrome (PCOS): Women with PCOS are at a higher risk of developing hyperinsulinism due to insulin resistance.
6. Gestational diabetes: Hyperinsulinism can occur during pregnancy, leading to gestational diabetes.
7. Acanthosis nigricans: A condition characterized by dark, velvety patches on the skin, often found in the armpits, neck, and groin area.
8. Cancer: Hyperinsulinism has been linked to an increased risk of certain types of cancer, such as breast, colon, and pancreatic cancer.
9. Cardiovascular disease: Excessive insulin can increase the risk of cardiovascular disease, including high blood pressure, heart disease, and stroke.
10. Cognitive impairment: Hyperinsulinism has been linked to cognitive impairment and an increased risk of dementia.

There are several causes of hyperinsulinism, including:

1. Insulin-producing tumors: Tumors that produce excessive amounts of insulin can lead to hyperinsulinism.
2. Familial hyperinsulinism: A genetic disorder that affects the regulation of insulin secretion and action.
3. Pancreatic beta-cell dysfunction: Dysfunction in the pancreatic beta cells, which produce insulin, can lead to hyperinsulinism.
4. Medications: Certain medications such as steroids and certain psychiatric drugs can cause hyperinsulinism.
5. Pituitary tumors: Tumors in the pituitary gland can lead to excessive secretion of growth hormone, which can stimulate insulin production.
6. Maternal diabetes during pregnancy: Women with diabetes during pregnancy may experience hyperinsulinism due to increased insulin resistance and higher insulin levels.
7. Gestational diabetes: High blood sugar during pregnancy can lead to hyperinsulinism.
8. Polycystic ovary syndrome (PCOS): Women with PCOS may experience hyperinsulinism due to insulin resistance and high insulin levels.
9. Cushing's syndrome: An endocrine disorder caused by excessive cortisol production can lead to hyperinsulinism.
10. Other medical conditions: Certain medical conditions such as thyroid disorders, adrenal gland disorders, and pituitary gland disorders can also cause hyperinsulinism.

It's important to note that some individuals with hyperinsulinism may not experience any symptoms, while others may experience a range of symptoms, including:

1. Weight gain
2. Fatigue
3. Headaches
4. Numbness or tingling in the hands and feet
5. Memory loss and difficulty concentrating
6. Mood changes, such as anxiety and depression
7. Skin problems, such as acne and thinning skin
8. Increased risk of heart disease and stroke
9. Growth retardation in children
10. Increased risk of developing type 2 diabetes

If you suspect that you or your child may have hyperinsulinism, it's important to consult with a healthcare professional for proper diagnosis and treatment. A doctor may perform a physical examination, take a medical history, and order blood tests to determine if hyperinsulinism is present and what may be causing it. Treatment options for hyperinsulinism will depend on the underlying cause of the condition. In some cases, medications such as metformin or other anti-diabetic drugs may be prescribed to help regulate blood sugar levels and reduce insulin production. In other cases, surgery or lifestyle changes may be necessary. With proper diagnosis and treatment, it is possible to manage hyperinsulinism and prevent or manage related health complications.

There are several types of dyslipidemias, including:

1. Hyperlipidemia: Elevated levels of lipids and lipoproteins in the blood, which can increase the risk of CVD.
2. Hypolipidemia: Low levels of lipids and lipoproteins in the blood, which can also increase the risk of CVD.
3. Mixed dyslipidemia: A combination of hyperlipidemia and hypolipidemia.
4. Familial dyslipidemia: An inherited condition that affects the levels of lipids and lipoproteins in the blood.
5. Acquired dyslipidemia: A condition caused by other factors, such as poor diet or medication side effects.

Dyslipidemias can be diagnosed through a variety of tests, including fasting blood sugar (FBS), lipid profile, and apolipoprotein testing. Treatment for dyslipidemias often involves lifestyle changes, such as dietary modifications and increased physical activity, as well as medications to lower cholesterol and triglycerides.

In conclusion, dyslipidemias are abnormalities in the levels or composition of lipids and lipoproteins in the blood that can increase the risk of CVD. They can be caused by a variety of factors and diagnosed through several tests. Treatment often involves lifestyle changes and medications to lower cholesterol and triglycerides.

Overnutrition can also occur in individuals who have a poor understanding of appropriate portion sizes or who have difficulty regulating their food intake due to psychological or environmental factors. Some common causes of overnutrition include:

1. Overeating: Consuming more food than the body needs, often due to emotional or social reasons.
2. Consuming high-calorie foods and beverages: Foods and drinks that are high in sugar, fat, and salt can lead to overnutrition.
3. Lack of physical activity: Insufficient exercise can contribute to weight gain and overnutrition.
4. Poor portion control: Eating large portions or not understanding appropriate serving sizes can lead to overnutrition.
5. Psychological factors: Stress, emotional eating, or binge eating can contribute to overnutrition.
6. Environmental factors: Living in an environment that does not support healthy eating, such as having limited access to healthy food options or being surrounded by high-calorie foods.

To prevent or manage overnutrition, individuals should focus on maintaining a balanced diet, portion control, regular physical activity, and managing stress and emotions around food. Treatment for overnutrition may involve weight loss programs, nutrition counseling, and lifestyle changes.

1. Impaired glucose tolerance (IGT): This is a condition where the body has difficulty regulating blood sugar levels after consuming a meal.
2. Impaired fasting glucose (IFG): This is a condition where the body has difficulty regulating blood sugar levels when fasting (not eating for a period of time).
3. Gestational diabetes: This is a type of diabetes that develops during pregnancy, usually in the second or third trimester.
4. Type 2 diabetes: This is a chronic condition where the body cannot effectively use insulin to regulate blood sugar levels.

The symptoms of glucose intolerance can vary depending on the type and severity of the condition. Some common symptoms include:

* High blood sugar levels
* Increased thirst and urination
* Fatigue
* Blurred vision
* Cuts or bruises that are slow to heal
* Tingling or numbness in the hands and feet

The diagnosis of glucose intolerance is typically made through a combination of physical examination, medical history, and laboratory tests such as:

* Fasting plasma glucose (FPG) test: This measures the level of glucose in the blood after an overnight fast.
* Oral glucose tolerance test (OGTT): This measures the body's ability to regulate blood sugar levels after consuming a sugary drink.
* Hemoglobin A1c (HbA1c) test: This measures the average blood sugar level over the past 2-3 months.

Treatment for glucose intolerance usually involves lifestyle changes such as:

* Eating a healthy, balanced diet that is low in added sugars and refined carbohydrates
* Increasing physical activity to help the body use insulin more effectively
* Losing weight if you are overweight or obese
* Monitoring blood sugar levels regularly

In some cases, medication may be prescribed to help manage blood sugar levels. These include:

* Metformin: This is a type of oral medication that helps the body use insulin more effectively.
* Sulfonylureas: These medications stimulate the release of insulin from the pancreas.
* Thiazolidinediones: These medications improve the body's sensitivity to insulin.

If left untreated, glucose intolerance can lead to a range of complications such as:

* Type 2 diabetes: This is a more severe form of glucose intolerance that can cause damage to the body's organs and tissues.
* Cardiovascular disease: High blood sugar levels can increase the risk of heart disease and stroke.
* Nerve damage: High blood sugar levels over an extended period can damage the nerves, leading to numbness, tingling, and pain in the hands and feet.
* Kidney damage: High blood sugar levels can damage the kidneys and lead to kidney disease.
* Eye damage: High blood sugar levels can damage the blood vessels in the eyes, leading to vision problems.

It is important to note that not everyone with glucose intolerance will develop these complications, but it is important to manage the condition to reduce the risk of these complications occurring.

Explanation: Genetic predisposition to disease is influenced by multiple factors, including the presence of inherited genetic mutations or variations, environmental factors, and lifestyle choices. The likelihood of developing a particular disease can be increased by inherited genetic mutations that affect the functioning of specific genes or biological pathways. For example, inherited mutations in the BRCA1 and BRCA2 genes increase the risk of developing breast and ovarian cancer.

The expression of genetic predisposition to disease can vary widely, and not all individuals with a genetic predisposition will develop the disease. Additionally, many factors can influence the likelihood of developing a particular disease, such as environmental exposures, lifestyle choices, and other health conditions.

Inheritance patterns: Genetic predisposition to disease can be inherited in an autosomal dominant, autosomal recessive, or multifactorial pattern, depending on the specific disease and the genetic mutations involved. Autosomal dominant inheritance means that a single copy of the mutated gene is enough to cause the disease, while autosomal recessive inheritance requires two copies of the mutated gene. Multifactorial inheritance involves multiple genes and environmental factors contributing to the development of the disease.

Examples of diseases with a known genetic predisposition:

1. Huntington's disease: An autosomal dominant disorder caused by an expansion of a CAG repeat in the Huntingtin gene, leading to progressive neurodegeneration and cognitive decline.
2. Cystic fibrosis: An autosomal recessive disorder caused by mutations in the CFTR gene, leading to respiratory and digestive problems.
3. BRCA1/2-related breast and ovarian cancer: An inherited increased risk of developing breast and ovarian cancer due to mutations in the BRCA1 or BRCA2 genes.
4. Sickle cell anemia: An autosomal recessive disorder caused by a point mutation in the HBB gene, leading to defective hemoglobin production and red blood cell sickling.
5. Type 1 diabetes: An autoimmune disease caused by a combination of genetic and environmental factors, including multiple genes in the HLA complex.

Understanding the genetic basis of disease can help with early detection, prevention, and treatment. For example, genetic testing can identify individuals who are at risk for certain diseases, allowing for earlier intervention and preventive measures. Additionally, understanding the genetic basis of a disease can inform the development of targeted therapies and personalized medicine."


There are several types of hyperlipidemia, including:

1. High cholesterol: This is the most common type of hyperlipidemia and is characterized by elevated levels of low-density lipoprotein (LDL) cholesterol, also known as "bad" cholesterol.
2. High triglycerides: This type of hyperlipidemia is characterized by elevated levels of triglycerides in the blood. Triglycerides are a type of fat found in the blood that is used for energy.
3. Low high-density lipoprotein (HDL) cholesterol: HDL cholesterol is known as "good" cholesterol because it helps remove excess cholesterol from the bloodstream and transport it to the liver for excretion. Low levels of HDL cholesterol can contribute to hyperlipidemia.

Symptoms of hyperlipidemia may include xanthomas (fatty deposits on the skin), corneal arcus (a cloudy ring around the iris of the eye), and tendon xanthomas (tender lumps under the skin). However, many people with hyperlipidemia have no symptoms at all.

Hyperlipidemia can be diagnosed through a series of blood tests that measure the levels of different types of cholesterol and triglycerides in the blood. Treatment for hyperlipidemia typically involves dietary changes, such as reducing intake of saturated fats and cholesterol, and increasing physical activity. Medications such as statins, fibric acid derivatives, and bile acid sequestrants may also be prescribed to lower cholesterol levels.

In severe cases of hyperlipidemia, atherosclerosis (hardening of the arteries) can occur, which can lead to cardiovascular disease, including heart attacks and strokes. Therefore, it is important to diagnose and treat hyperlipidemia early on to prevent these complications.

1. Preeclampsia: A condition characterized by high blood pressure during pregnancy, which can lead to complications such as stroke or premature birth.
2. Gestational diabetes: A type of diabetes that develops during pregnancy, which can cause complications for both the mother and the baby if left untreated.
3. Placenta previa: A condition in which the placenta is located low in the uterus, covering the cervix, which can cause bleeding and other complications.
4. Premature labor: Labor that occurs before 37 weeks of gestation, which can increase the risk of health problems for the baby.
5. Fetal distress: A condition in which the fetus is not getting enough oxygen, which can lead to serious health problems or even death.
6. Postpartum hemorrhage: Excessive bleeding after delivery, which can be life-threatening if left untreated.
7. Cesarean section (C-section) complications: Complications that may arise during a C-section, such as infection or bleeding.
8. Maternal infections: Infections that the mother may contract during pregnancy or childbirth, such as group B strep or urinary tract infections.
9. Preterm birth: Birth that occurs before 37 weeks of gestation, which can increase the risk of health problems for the baby.
10. Chromosomal abnormalities: Genetic disorders that may affect the baby's growth and development, such as Down syndrome or Turner syndrome.

It is important for pregnant women to receive regular prenatal care to monitor for any potential complications and ensure a healthy pregnancy outcome. In some cases, pregnancy complications may require medical interventions, such as hospitalization or surgery, to ensure the safety of both the mother and the baby.

1. Vision loss or blindness
2. Developmental delays and intellectual disability
3. Speech and language difficulties
4. Poor coordination and balance
5. Skeletal abnormalities such as short stature, short arms, and curved spine
6. Kidney problems
7. Hearing loss
8. Increased risk of infections
9. Cleft palate or other facial defects
10. Delayed puberty or absent menstruation in females

The syndrome is caused by mutations in the Bardet-Biedl genes, which are responsible for the development and function of the body's sensory and motor systems. It is inherited in an autosomal recessive pattern, meaning that a child must inherit two copies of the mutated gene - one from each parent - to develop the condition.

There is currently no cure for Bardet-Biedl Syndrome, but treatment and management options are available to help manage the symptoms and improve quality of life. These may include:

1. Vision aids such as glasses or contact lenses
2. Speech and language therapy
3. Physical therapy to improve coordination and balance
4. Occupational therapy to develop daily living skills
5. Medications to manage infections, seizures, or other complications
6. Surgery to correct physical abnormalities such as cleft palate or spinal deformities
7. Hormone replacement therapy for delayed puberty or absent menstruation in females.

The prognosis for individuals with Bardet-Biedl Syndrome varies depending on the severity of the symptoms and the presence of any additional health issues. With appropriate management and support, many individuals with the condition are able to lead fulfilling lives and achieve their goals. However, the syndrome can be associated with a higher risk of certain health complications, such as kidney disease or respiratory infections, which can impact life expectancy.

Prenatal Exposure Delayed Effects can affect various aspects of the child's development, including:

1. Physical growth and development: PDEDs can lead to changes in the child's physical growth patterns, such as reduced birth weight, short stature, or delayed puberty.
2. Brain development: Prenatal exposure to certain substances can affect brain development, leading to learning disabilities, memory problems, and cognitive delays.
3. Behavioral and emotional development: Children exposed to PDEDs may exhibit behavioral and emotional difficulties, such as anxiety, depression, or attention deficit hyperactivity disorder (ADHD).
4. Immune system functioning: Prenatal exposure to certain substances can affect the immune system's development, making children more susceptible to infections and autoimmune diseases.
5. Reproductive health: Exposure to certain chemicals during fetal development may disrupt the reproductive system, leading to fertility problems or an increased risk of infertility later in life.

The diagnosis of Prenatal Exposure Delayed Effects often requires a comprehensive medical history and physical examination, as well as specialized tests such as imaging studies or laboratory assessments. Treatment for PDEDs typically involves addressing the underlying cause of exposure and providing appropriate interventions to manage any associated symptoms or developmental delays.

In summary, Prenatal Exposure Delayed Effects can have a profound impact on a child's growth, development, and overall health later in life. It is essential for healthcare providers to be aware of the potential risks and to monitor children exposed to substances during fetal development for any signs of PDEDs. With early diagnosis and appropriate interventions, it may be possible to mitigate or prevent some of these effects and improve outcomes for affected children.

Types of Hypothalamic Diseases:

1. Hypothalamic hamartoma: A benign tumor that develops in the hypothalamus and can cause a variety of symptoms such as seizures, obesity, and developmental delays.
2. Hypothalamic glioma: A malignant tumor that arises in the hypothalamus and can cause similar symptoms to hypothalamic hamartoma.
3. Hypothalamic malformations: Congenital abnormalities that affect the development of the hypothalamus, leading to various neurological symptoms such as seizures, intellectual disability, and behavioral problems.
4. Hypothalamic infarction: A condition where there is a lack of blood flow to the hypothalamus, leading to damage to the tissue and potentially causing a range of symptoms including stroke-like symptoms.
5. Hypothalamic lesions: Damage to the hypothalamus caused by traumatic brain injury, infection, or other factors, which can lead to a range of neurological symptoms.

Symptoms of Hypothalamic Diseases:

The symptoms of hypothalamic diseases can vary depending on the specific condition and the severity of the damage to the hypothalamus. Some common symptoms include:

* Seizures
* Headaches
* Vision problems
* Balance and coordination difficulties
* Weight changes (gain or loss)
* Sleep disturbances
* Mood changes (depression, anxiety)
* Behavioral problems (aggression, irritability)
* Intellectual disability

Diagnosis of Hypothalamic Diseases:

Diagnosing hypothalamic diseases can be challenging and may require a range of tests and evaluations. These may include:

1. Physical examination and medical history: A thorough evaluation of the patient's symptoms, medical history, and physical condition.
2. Imaging tests: Such as CT or MRI scans to visualize the brain and identify any structural abnormalities or lesions in the hypothalamus.
3. Blood tests: To check for hormone levels and other markers that can help diagnose specific conditions.
4. EEG and other neurological tests: To evaluate the patient's neurological function and identify any potential seizure activity or other abnormalities.
5. Genetic testing: If the condition is suspected to be inherited, genetic testing may be performed to identify mutations or variations in genes that can contribute to hypothalamic diseases.

Treatment of Hypothalamic Diseases:

The treatment of hypothalamic diseases depends on the specific condition and the severity of the symptoms. Some common treatments include:

1. Medications: Such as anticonvulsants, hormone replacement therapy, and pain management medications to control seizures, hormonal imbalances, and pain.
2. Hormone replacement therapy: To replace hormones that are deficient or imbalanced.
3. Surgery: May be necessary to remove a tumor or repair a structural abnormality in the hypothalamus.
4. Lifestyle modifications: Such as changes to diet, exercise, and sleep habits to manage symptoms and improve quality of life.
5. Rehabilitation therapy: To help regain lost functions and improve daily living skills.

Prognosis of Hypothalamic Diseases:

The prognosis for hypothalamic diseases varies depending on the specific condition and the severity of the symptoms. Some conditions may have a good prognosis with appropriate treatment, while others may have a poorer outcome. In general, early diagnosis and treatment can improve the chances of a better outcome.

Living with Hypothalamic Diseases:

Living with a hypothalamic disease can be challenging and may require significant lifestyle modifications and ongoing medical care. However, with the right treatment and support, many people are able to manage their symptoms and improve their quality of life. Some tips for living with a hypothalamic disease include:

1. Educate yourself about your condition and its management.
2. Work closely with your healthcare provider to develop a personalized treatment plan.
3. Make lifestyle modifications such as changes to diet, exercise, and sleep habits.
4. Join a support group to connect with others who are living with similar conditions.
5. Seek mental health support if needed to cope with the emotional impact of the condition.

In conclusion, hypothalamic diseases can have a significant impact on quality of life, but with early diagnosis and appropriate treatment, many people are able to manage their symptoms and improve their outcomes. It is important to work closely with a healthcare provider to develop a personalized treatment plan and make lifestyle modifications as needed. With the right support and resources, it is possible to live a fulfilling life with a hypothalamic disease.

1. Heart Disease: High blood sugar levels can damage the blood vessels and increase the risk of heart disease, which includes conditions like heart attacks, strokes, and peripheral artery disease.
2. Kidney Damage: Uncontrolled diabetes can damage the kidneys over time, leading to chronic kidney disease and potentially even kidney failure.
3. Nerve Damage: High blood sugar levels can damage the nerves in the body, causing numbness, tingling, and pain in the hands and feet. This is known as diabetic neuropathy.
4. Eye Problems: Diabetes can cause changes in the blood vessels of the eyes, leading to vision problems and even blindness. This is known as diabetic retinopathy.
5. Infections: People with diabetes are more prone to developing skin infections, urinary tract infections, and other types of infections due to their weakened immune system.
6. Amputations: Poor blood flow and nerve damage can lead to amputations of the feet or legs if left untreated.
7. Cognitive Decline: Diabetes has been linked to an increased risk of cognitive decline and dementia.
8. Sexual Dysfunction: Men with diabetes may experience erectile dysfunction, while women with diabetes may experience decreased sexual desire and vaginal dryness.
9. Gum Disease: People with diabetes are more prone to developing gum disease and other oral health problems due to their increased risk of infection.
10. Flu and Pneumonia: Diabetes can weaken the immune system, making it easier to catch the flu and pneumonia.

It is important for people with diabetes to manage their condition properly to prevent or delay these complications from occurring. This includes monitoring blood sugar levels regularly, taking medication as prescribed by a doctor, and following a healthy diet and exercise plan. Regular check-ups with a healthcare provider can also help identify any potential complications early on and prevent them from becoming more serious.

There are several causes of hypertriglyceridemia, including:

* Genetics: Some people may inherit a tendency to have high triglyceride levels due to genetic mutations that affect the genes involved in triglyceride metabolism.
* Obesity: Excess body weight is associated with higher triglyceride levels, as there is more fat available for energy.
* Diabetes: Both type 1 and type 2 diabetes can lead to high triglyceride levels due to insulin resistance and altered glucose metabolism.
* High-carbohydrate diet: Consuming high amounts of carbohydrates, particularly refined or simple carbohydrates, can cause a spike in blood triglycerides.
* Alcohol consumption: Drinking too much alcohol can increase triglyceride levels in the blood.
* Certain medications: Some drugs, such as anabolic steroids and some antidepressants, can raise triglyceride levels.
* Underlying medical conditions: Certain medical conditions, such as hypothyroidism, kidney disease, and polycystic ovary syndrome (PCOS), can also contribute to high triglyceride levels.

Hypertriglyceridemia is typically diagnosed with a blood test that measures the level of triglycerides in the blood. Treatment options for hypertriglyceridemia depend on the underlying cause of the condition, but may include lifestyle modifications such as weight loss, dietary changes, and medications to lower triglyceride levels.

There are several possible causes of hyperglycemia, including:

1. Diabetes: This is a chronic condition where the body either does not produce enough insulin or cannot use insulin effectively.
2. Insulin resistance: This occurs when the body's cells become less responsive to insulin, leading to high blood sugar levels.
3. Pancreatitis: This is inflammation of the pancreas, which can lead to high blood sugar levels.
4. Cushing's syndrome: This is a rare hormonal disorder that can cause high blood sugar levels.
5. Medications: Certain medications, such as steroids and some types of antidepressants, can raise blood sugar levels.
6. Stress: Stress can cause the release of hormones such as cortisol and adrenaline, which can raise blood sugar levels.
7. Infections: Certain infections, such as pneumonia or urinary tract infections, can cause high blood sugar levels.
8. Trauma: Traumatic injuries can cause high blood sugar levels due to the release of stress hormones.
9. Surgery: Some types of surgery, such as heart bypass surgery, can cause high blood sugar levels.
10. Pregnancy: High blood sugar levels can occur during pregnancy, especially in women who have a history of gestational diabetes.

Hyperglycemia can cause a range of symptoms, including:

1. Increased thirst and urination
2. Fatigue
3. Blurred vision
4. Headaches
5. Cuts or bruises that are slow to heal
6. Tingling or numbness in the hands and feet
7. Dry, itchy skin
8. Flu-like symptoms, such as weakness, dizziness, and stomach pain
9. Recurring skin, gum, or bladder infections
10. Sexual dysfunction in men and women

If left untreated, hyperglycemia can lead to serious complications, including:

1. Diabetic ketoacidosis (DKA): A life-threatening condition that occurs when the body produces high levels of ketones, which are acidic substances that can cause confusion, nausea, and vomiting.
2. Hypoglycemia: Low blood sugar levels that can cause dizziness, confusion, and even loss of consciousness.
3. Nerve damage: High blood sugar levels over an extended period can damage the nerves, leading to numbness, tingling, and pain in the hands and feet.
4. Kidney damage: The kidneys may become overworked and damaged if they are unable to filter out the excess glucose in the blood.
5. Eye damage: High blood sugar levels can cause damage to the blood vessels in the eyes, leading to vision loss and blindness.
6. Cardiovascular disease: Hyperglycemia can increase the risk of cardiovascular disease, including heart attacks, strokes, and peripheral artery disease.
7. Cognitive impairment: Hyperglycemia has been linked to cognitive impairment and an increased risk of dementia.

It is essential to manage hyperglycemia by making lifestyle changes, such as following a healthy diet, regular exercise, and taking medication if prescribed by a healthcare professional. Monitoring blood sugar levels regularly can help identify the signs of hyperglycemia and prevent long-term complications.

The main symptoms of OSA are:

1. Loud snoring
2. Pauses in breathing during sleep (apneas)
3. Waking up with a dry mouth or sore throat
4. Morning headaches
5. Difficulty concentrating or feeling tired during the day

OSA is caused by a physical blockage of the airway, usually due to excess tissue in the throat or a large tongue. This can be exacerbated by factors such as being overweight, having a small jaw or narrow airway, or drinking alcohol before bedtime.

If left untreated, OSA can lead to serious complications such as high blood pressure, heart disease, and stroke. Treatment options for OSA include lifestyle changes (such as weight loss and avoiding alcohol), oral appliances (such as a mandibular advancement device), and continuous positive airway pressure (CPAP) therapy. In severe cases, surgery may be necessary to remove excess tissue in the throat or widen the airway.

It is important for individuals who suspect they may have OSA to consult with a healthcare professional for proper diagnosis and treatment. A sleep study can be conducted to determine the severity of the condition and rule out other potential causes of sleep disruptions.

1. Irregular menstrual cycles, or amenorrhea (the absence of periods).
2. Cysts on the ovaries, which are fluid-filled sacs that can be detected by ultrasound.
3. Elevated levels of androgens (male hormones) in the body, which can cause a range of symptoms including acne, excessive hair growth, and male pattern baldness.
4. Insulin resistance, which is a condition in which the body's cells do not respond properly to insulin, leading to high blood sugar levels.

PCOS is a complex disorder, and there is no single cause. However, genetics, hormonal imbalances, and insulin resistance are thought to play a role in its development. It is estimated that 5-10% of women of childbearing age have PCOS, making it one of the most common endocrine disorders affecting women.

There are several symptoms of PCOS, including:

1. Irregular menstrual cycles or amenorrhea
2. Weight gain or obesity
3. Acne
4. Excessive hair growth on the face, chest, and back
5. Male pattern baldness
6. Infertility or difficulty getting pregnant
7. Mood changes, such as depression and anxiety
8. Sleep apnea

PCOS can be diagnosed through a combination of physical examination, medical history, and laboratory tests, including:

1. Pelvic exam: A doctor will examine the ovaries and uterus to look for cysts or other abnormalities.
2. Ultrasound: An ultrasound can be used to detect cysts on the ovaries and to evaluate the thickness of the uterine lining.
3. Hormone testing: Blood tests can be used to measure levels of androgens, estrogen, and progesterone.
4. Glucose tolerance test: This test is used to check for insulin resistance, which is a common finding in women with PCOS.
5. Laparoscopy: A small camera inserted through a small incision in the abdomen can be used to visualize the ovaries and uterus and to diagnose PCOS.

There is no cure for PCOS, but it can be managed with lifestyle changes and medication. Treatment options include:

1. Weight loss: Losing weight can improve insulin sensitivity and reduce androgen levels.
2. Hormonal birth control: Birth control pills or other hormonal contraceptives can help regulate menstrual cycles and reduce androgen levels.
3. Fertility medications: Clomiphene citrate and letrozole are commonly used to stimulate ovulation in women with PCOS.
4. Injectable fertility medications: Gonadotropins, such as follicle-stimulating hormone (FSH) and luteinizing hormone (LH), can be used to stimulate ovulation.
5. Surgery: Laparoscopic ovarian drilling or laser surgery can improve ovulation and fertility in women with PCOS.
6. Assisted reproductive technology (ART): In vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) can be used to help women with PCOS conceive.
7. Alternative therapies: Some complementary and alternative therapies, such as acupuncture and herbal supplements, may be helpful in managing symptoms of PCOS.

It is important for women with PCOS to work closely with their healthcare provider to develop a treatment plan that meets their individual needs and goals. With appropriate treatment, many women with PCOS can improve their menstrual regularity, fertility, and overall health.

PWS is characterized by a range of physical, cognitive, and behavioral symptoms, including:

1. Delayed growth and development: Individuals with PWS often have slowed growth before birth and may be born with low birth weight. They may also experience delayed puberty and short stature compared to their peers.
2. Intellectual disability: Many individuals with PWS have intellectual disability, which can range from mild to severe.
3. Behavioral problems: PWS is often associated with behavioral challenges, such as attention deficit hyperactivity disorder (ADHD), anxiety, and obsessive-compulsive disorder (OCD).
4. Feeding and eating difficulties: Individuals with PWS may have difficulty feeding and swallowing, which can lead to nutritional deficiencies and other health problems. They may also experience a condition called "hyperphagia," which is characterized by excessive hunger and overeating.
5. Sleep disturbances: PWS is often associated with sleep disturbances, such as insomnia and restlessness.
6. Short stature: Individuals with PWS tend to be shorter than their peers, with an average adult height of around 4 feet 10 inches (147 cm).
7. Body composition: PWS is often characterized by a high percentage of body fat, which can increase the risk of obesity and other health problems.
8. Hormonal imbalances: PWS can disrupt the balance of hormones in the body, leading to issues such as hypogonadism (low testosterone levels) and hypothyroidism (underactive thyroid).
9. Dental problems: Individuals with PWS are at increased risk of dental problems, including tooth decay and gum disease.
10. Vision and hearing problems: Some individuals with PWS may experience vision and hearing problems, such as nearsightedness, farsightedness, and hearing loss.

It's important to note that every individual with PWS is unique, and not all will experience all of these symptoms. Additionally, the severity of the disorder can vary widely from person to person. With proper medical care and management, however, many individuals with PWS can lead fulfilling and productive lives.

Low birth weight is defined as less than 2500 grams (5 pounds 8 ounces) and is associated with a higher risk of health problems, including respiratory distress, infection, and developmental delays. Premature birth is also a risk factor for low birth weight, as premature infants may not have had enough time to grow to a healthy weight before delivery.

On the other hand, high birth weight is associated with an increased risk of macrosomia, a condition in which the baby is significantly larger than average and may require a cesarean section (C-section) or assisted delivery. Macrosomia can also increase the risk of injury to the mother during delivery.

Birth weight can be influenced by various factors during pregnancy, including maternal nutrition, prenatal care, and fetal growth patterns. However, it is important to note that birth weight alone is not a definitive indicator of a baby's health or future development. Other factors, such as the baby's overall physical condition, Apgar score (a measure of the baby's well-being at birth), and postnatal care, are also important indicators of long-term health outcomes.

There are several types of hepatitis C, including genotype 1, which is the most common and accounts for approximately 70% of cases in the United States. Other genotypes include 2, 3, 4, 5, and 6. The symptoms of hepatitis C can range from mild to severe and may include fatigue, fever, loss of appetite, nausea, vomiting, joint pain, jaundice (yellowing of the skin and eyes), dark urine, pale stools, and itching all over the body. Some people with hepatitis C may not experience any symptoms at all.

Hepatitis C is diagnosed through a combination of blood tests that detect the presence of antibodies against HCV or the virus itself. Treatment typically involves a combination of medications, including interferon and ribavirin, which can cure the infection but may have side effects such as fatigue, nausea, and depression. In recent years, new drugs known as direct-acting antivirals (DAAs) have become available, which can cure the infection with fewer side effects and in a shorter period of time.

Prevention measures for hepatitis C include avoiding sharing needles or other drug paraphernalia, using condoms to prevent sexual transmission, and ensuring that any tattoos or piercings are performed with sterilized equipment. Vaccines are also available for people who are at high risk of contracting the virus, such as healthcare workers and individuals who engage in high-risk behaviors.

Overall, hepatitis C is a serious and common liver disease that can lead to significant health complications if left untreated. Fortunately, with advances in medical technology and treatment options, it is possible to manage and cure the virus with proper care and attention.

Definition:

* A form of diabetes that develops during pregnancy
* Caused by hormonal changes and insulin resistance
* Can lead to complications for both the mother and the baby
* Typically goes away after childbirth

The burden of chronic diseases is significant, with over 70% of deaths worldwide attributed to them, according to the World Health Organization (WHO). In addition to the physical and emotional toll they take on individuals and their families, chronic diseases also pose a significant economic burden, accounting for a large proportion of healthcare expenditure.

In this article, we will explore the definition and impact of chronic diseases, as well as strategies for managing and living with them. We will also discuss the importance of early detection and prevention, as well as the role of healthcare providers in addressing the needs of individuals with chronic diseases.

What is a Chronic Disease?

A chronic disease is a condition that lasts for an extended period of time, often affecting daily life and activities. Unlike acute diseases, which have a specific beginning and end, chronic diseases are long-term and persistent. Examples of chronic diseases include:

1. Diabetes
2. Heart disease
3. Arthritis
4. Asthma
5. Cancer
6. Chronic obstructive pulmonary disease (COPD)
7. Chronic kidney disease (CKD)
8. Hypertension
9. Osteoporosis
10. Stroke

Impact of Chronic Diseases

The burden of chronic diseases is significant, with over 70% of deaths worldwide attributed to them, according to the WHO. In addition to the physical and emotional toll they take on individuals and their families, chronic diseases also pose a significant economic burden, accounting for a large proportion of healthcare expenditure.

Chronic diseases can also have a significant impact on an individual's quality of life, limiting their ability to participate in activities they enjoy and affecting their relationships with family and friends. Moreover, the financial burden of chronic diseases can lead to poverty and reduce economic productivity, thus having a broader societal impact.

Addressing Chronic Diseases

Given the significant burden of chronic diseases, it is essential that we address them effectively. This requires a multi-faceted approach that includes:

1. Lifestyle modifications: Encouraging healthy behaviors such as regular physical activity, a balanced diet, and smoking cessation can help prevent and manage chronic diseases.
2. Early detection and diagnosis: Identifying risk factors and detecting diseases early can help prevent or delay their progression.
3. Medication management: Effective medication management is crucial for controlling symptoms and slowing disease progression.
4. Multi-disciplinary care: Collaboration between healthcare providers, patients, and families is essential for managing chronic diseases.
5. Health promotion and disease prevention: Educating individuals about the risks of chronic diseases and promoting healthy behaviors can help prevent their onset.
6. Addressing social determinants of health: Social determinants such as poverty, education, and employment can have a significant impact on health outcomes. Addressing these factors is essential for reducing health disparities and improving overall health.
7. Investing in healthcare infrastructure: Investing in healthcare infrastructure, technology, and research is necessary to improve disease detection, diagnosis, and treatment.
8. Encouraging policy change: Policy changes can help create supportive environments for healthy behaviors and reduce the burden of chronic diseases.
9. Increasing public awareness: Raising public awareness about the risks and consequences of chronic diseases can help individuals make informed decisions about their health.
10. Providing support for caregivers: Chronic diseases can have a significant impact on family members and caregivers, so providing them with support is essential for improving overall health outcomes.

Conclusion

Chronic diseases are a major public health burden that affect millions of people worldwide. Addressing these diseases requires a multi-faceted approach that includes lifestyle changes, addressing social determinants of health, investing in healthcare infrastructure, encouraging policy change, increasing public awareness, and providing support for caregivers. By taking a comprehensive approach to chronic disease prevention and management, we can improve the health and well-being of individuals and communities worldwide.

Disease progression can be classified into several types based on the pattern of worsening:

1. Chronic progressive disease: In this type, the disease worsens steadily over time, with a gradual increase in symptoms and decline in function. Examples include rheumatoid arthritis, osteoarthritis, and Parkinson's disease.
2. Acute progressive disease: This type of disease worsens rapidly over a short period, often followed by periods of stability. Examples include sepsis, acute myocardial infarction (heart attack), and stroke.
3. Cyclical disease: In this type, the disease follows a cycle of worsening and improvement, with periodic exacerbations and remissions. Examples include multiple sclerosis, lupus, and rheumatoid arthritis.
4. Recurrent disease: This type is characterized by episodes of worsening followed by periods of recovery. Examples include migraine headaches, asthma, and appendicitis.
5. Catastrophic disease: In this type, the disease progresses rapidly and unpredictably, with a poor prognosis. Examples include cancer, AIDS, and organ failure.

Disease progression can be influenced by various factors, including:

1. Genetics: Some diseases are inherited and may have a predetermined course of progression.
2. Lifestyle: Factors such as smoking, lack of exercise, and poor diet can contribute to disease progression.
3. Environmental factors: Exposure to toxins, allergens, and other environmental stressors can influence disease progression.
4. Medical treatment: The effectiveness of medical treatment can impact disease progression, either by slowing or halting the disease process or by causing unintended side effects.
5. Co-morbidities: The presence of multiple diseases or conditions can interact and affect each other's progression.

Understanding the type and factors influencing disease progression is essential for developing effective treatment plans and improving patient outcomes.

Some common types of glucose metabolism disorders include:

1. Diabetes mellitus: This is a group of diseases characterized by high blood sugar levels due to defects in insulin production, insulin action, or both. There are several types of diabetes, including type 1, type 2, and gestational diabetes.
2. Hypoglycemia: This is a condition characterized by low blood sugar levels, typically below 70 mg/dL. It can be caused by a variety of factors, including medication side effects, hormonal changes, or certain medical conditions.
3. Hyperglycemia: This is a condition characterized by high blood sugar levels, typically above 140 mg/dL. It can be caused by a variety of factors, including diabetes, stress, or medication side effects.
4. Insulin resistance: This is a condition in which the body's cells become less responsive to insulin, leading to high blood sugar levels. It is often associated with type 2 diabetes and obesity.
5. Metabolic syndrome: This is a cluster of conditions that increase the risk of developing type 2 diabetes and cardiovascular disease. These conditions include central obesity, hypertension, high triglycerides, low HDL cholesterol, and high blood sugar.

Glucose metabolism disorders can have serious complications if left untreated, including nerve damage, kidney damage, and an increased risk of heart disease and stroke. Treatment for these disorders typically involves a combination of dietary changes, medication, and lifestyle modifications.

The symptoms of hepatitis B can range from mild to severe and may include fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, pale stools, joint pain, and jaundice (yellowing of the skin and eyes). In some cases, hepatitis B can be asymptomatic, meaning that individuals may not experience any symptoms at all.

Hepatitis B is diagnosed through blood tests that detect the presence of HBV antigens or antibodies in the body. Treatment for acute hepatitis B typically involves rest, hydration, and medication to manage symptoms, while chronic hepatitis B may require ongoing therapy with antiviral drugs to suppress the virus and prevent liver damage.

Preventive measures for hepatitis B include vaccination, which is recommended for individuals at high risk of infection, such as healthcare workers, sexually active individuals, and those traveling to areas where HBV is common. In addition, safe sex practices, avoiding sharing of needles or other bodily fluids, and proper sterilization of medical equipment can help reduce the risk of transmission.

Overall, hepatitis B is a serious infection that can have long-term consequences for liver health, and it is important to take preventive measures and seek medical attention if symptoms persist or worsen over time.

The disease begins with endothelial dysfunction, which allows lipid accumulation in the artery wall. Macrophages take up oxidized lipids and become foam cells, which die and release their contents, including inflammatory cytokines, leading to further inflammation and recruitment of more immune cells.

The atherosclerotic plaque can rupture or ulcerate, leading to the formation of a thrombus that can occlude the blood vessel, causing ischemia or infarction of downstream tissues. This can lead to various cardiovascular diseases such as myocardial infarction (heart attack), stroke, and peripheral artery disease.

Atherosclerosis is a multifactorial disease that is influenced by genetic and environmental factors such as smoking, hypertension, diabetes, high cholesterol levels, and obesity. It is diagnosed by imaging techniques such as angiography, ultrasound, or computed tomography (CT) scans.

Treatment options for atherosclerosis include lifestyle modifications such as smoking cessation, dietary changes, and exercise, as well as medications such as statins, beta blockers, and angiotensin-converting enzyme (ACE) inhibitors. In severe cases, surgical interventions such as bypass surgery or angioplasty may be necessary.

In conclusion, atherosclerosis is a complex and multifactorial disease that affects the arteries and can lead to various cardiovascular diseases. Early detection and treatment can help prevent or slow down its progression, reducing the risk of complications and improving patient outcomes.

The American Diabetes Association (ADA) defines prediabetes as having a fasting blood sugar level of 100-125 mg/dL or a 2-hour postprandial (after meal) blood sugar level of 140-199 mg/dL.

The prediabetic state is characterized by insulin resistance, which means that the body's cells are not able to effectively use insulin, a hormone produced by the pancreas that regulates blood sugar levels. As a result, blood sugar levels begin to rise, but not high enough to be classified as diabetes.

Prediabetes is a reversible condition, and individuals with this condition can take steps to lower their blood sugar levels and prevent the development of type 2 diabetes. Lifestyle changes such as losing weight, increasing physical activity, and following a healthy diet can help improve insulin sensitivity and reduce the risk of developing diabetes. In some cases, medication may also be prescribed to help lower blood sugar levels.

It's important to note that not everyone with prediabetes will develop type 2 diabetes, but it is a significant risk factor. Early detection and intervention can help prevent or delay the progression to type 2 diabetes, and improve overall health outcomes.

1. Maternal nutritional deficiencies: A mother's diet before conception can affect the developing fetus, and a lack of essential nutrients such as folate, iron, and iodine can increase the risk of birth defects.
2. Exposure to toxins: Exposure to harmful substances such as lead, mercury, and pesticides can increase the risk of preconception injuries.
3. Chronic stress: Prolonged stress can disrupt hormone levels and ovulation, making it more difficult to conceive.
4. Pre-existing medical conditions: Certain health conditions such as diabetes, hypertension, and thyroid disorders can increase the risk of preconception injuries.
5. Lifestyle factors: Smoking, excessive alcohol consumption, and drug use can all cause preconception injuries.
6. Infections: Certain infections such as rubella, toxoplasmosis, and listeriosis can cause preconception injuries if contracted during the window of time when the fertilized egg is implanting in the uterus.
7. Physical trauma: A severe injury or accident can potentially cause preconception injuries.
8. Radiation exposure: Exposure to high levels of radiation can increase the risk of preconception injuries.
9. Medications: Certain medications such as chemotherapy drugs and some antidepressants can increase the risk of preconception injuries.
10. Age: Women's eggs become less fertile with age, and the risk of preconception injuries increases after the age of 35.

Preconception injuries can have a significant impact on fetal development and can increase the risk of various birth defects and complications during pregnancy. It is important for women to take steps to minimize their risk of preconception injuries, such as avoiding certain medications and infections, maintaining a healthy lifestyle, and seeking medical advice before attempting to conceive.

The effects of sleep deprivation can be severe and long-lasting, including:

1. Impaired cognitive function: Sleep deprivation can affect attention, memory, and decision-making skills, making it more difficult to perform daily tasks and make sound judgments.
2. Emotional distress: Lack of sleep can lead to irritability, anxiety, and depression, which can negatively impact relationships and overall well-being.
3. Physical health problems: Chronic sleep deprivation has been linked to an increased risk of obesity, diabetes, cardiovascular disease, and immune system dysfunction.
4. Impaired motor function: Sleep deprivation can cause coordination problems, clumsiness, and a higher risk of accidents, particularly in activities that require attention and quick reflexes (e.g., driving).
5. Premature aging: Chronic sleep deprivation can accelerate the aging process and reduce the body's ability to repair and regenerate cells.
6. Reduced productivity and performance: Sleep deprivation can lead to decreased productivity, poor work quality, and increased absenteeism, which can negatively impact career advancement and financial stability.
7. Increased risk of accidents and injuries: Drowsy driving and workplace accidents are common consequences of sleep deprivation, which can result in fatalities and long-term disabilities.
8. Weakened immune system: Sleep deprivation can weaken the immune system, making it more difficult to fight off infections and diseases.
9. Negative impact on relationships: Sleep deprivation can lead to mood swings, irritability, and difficulty interacting with others, which can strain personal and professional relationships.
10. Increased risk of mental health disorders: Chronic sleep deprivation has been linked to an increased risk of developing anxiety, depression, and other mental health disorders.

To avoid these negative consequences, it's essential to prioritize sleep and make it a critical component of your daily routine. Establishing a consistent sleep schedule, creating a sleep-conducive environment, and practicing relaxation techniques can help improve sleep quality and duration. Additionally, avoiding stimulating activities before bedtime, limiting exposure to electronic screens, and seeking professional help if sleep problems persist can contribute to better overall health and well-being.

The most common types of eating disorders include:

1. Anorexia Nervosa: This is characterized by a severe restriction of food intake, leading to a significantly low body weight. Individuals with anorexia nervosa may have a distorted body image and may view themselves as being overweight, even if they are underweight.
2. Bulimia Nervosa: This is characterized by episodes of binge eating followed by purging, such as vomiting or using laxatives, to rid the body of the consumed food. This can lead to a cycle of guilt and shame, and can have serious physical consequences such as electrolyte imbalances and gastrointestinal problems.
3. Binge Eating Disorder: This is characterized by episodes of uncontrolled eating, often accompanied by feelings of guilt and shame. Unlike bulimia nervosa, there is no purging or compensatory behaviors to rid the body of the consumed food.
4. Other specified feeding or eating disorders (OSFED): This category includes a range of eating disorders that do not meet the criteria for anorexia nervosa, bulimia nervosa, or binge eating disorder. Examples include orthorexia nervosa (an obsession with healthy eating), avoidant/restrictive food intake disorder (a lack of interest in eating or a fear of eating), and pica (eating non-food items).

Eating disorders can have serious physical and emotional consequences, including:

1. Malnutrition: Eating disorders can lead to malnutrition, which can cause a range of health problems, including fatigue, hair loss, and poor wound healing.
2. Electrolyte imbalances: Eating disorders can also lead to electrolyte imbalances, which can cause heart problems, muscle weakness, and other complications.
3. Tooth decay and gum disease: Frequent vomiting can erode tooth enamel and lead to tooth decay and gum disease.
4. Digestive problems: Eating disorders can cause digestive problems such as constipation, diarrhea, and acid reflux.
5. Hormonal imbalances: Eating disorders can disrupt hormone levels, leading to menstrual irregularities, infertility, and other hormone-related problems.
6. Anxiety and depression: Eating disorders can also contribute to anxiety and depression, which can make it more difficult to recover from the eating disorder.
7. Social isolation: Eating disorders can lead to social isolation, as individuals may avoid social situations where food is involved or feel ashamed of their eating habits.
8. Body image distortion: Eating disorders can also cause body image distortion, leading to a negative and unrealistic view of one's body.
9. Osteoporosis: Eating disorders can increase the risk of osteoporosis, particularly in individuals who have been suffering from the disorder for a long time or who have experienced significant weight loss.
10. Increased risk of suicide: Eating disorders can also increase the risk of suicide, as individuals may feel overwhelmed by their symptoms and struggling to cope with the emotional and physical consequences of the disorder.

It's important to note that these complications can be life-threatening and require prompt medical attention. If you or someone you know is struggling with an eating disorder, it's essential to seek professional help from a mental health professional, a registered dietitian, or a primary care physician. With proper treatment and support, individuals can recover from eating disorders and lead a healthy and fulfilling life.

1. Infection: Bacterial or viral infections can develop after surgery, potentially leading to sepsis or organ failure.
2. Adhesions: Scar tissue can form during the healing process, which can cause bowel obstruction, chronic pain, or other complications.
3. Wound complications: Incisional hernias, wound dehiscence (separation of the wound edges), and wound infections can occur.
4. Respiratory problems: Pneumonia, respiratory failure, and atelectasis (collapsed lung) can develop after surgery, particularly in older adults or those with pre-existing respiratory conditions.
5. Cardiovascular complications: Myocardial infarction (heart attack), cardiac arrhythmias, and cardiac failure can occur after surgery, especially in high-risk patients.
6. Renal (kidney) problems: Acute kidney injury or chronic kidney disease can develop postoperatively, particularly in patients with pre-existing renal impairment.
7. Neurological complications: Stroke, seizures, and neuropraxia (nerve damage) can occur after surgery, especially in patients with pre-existing neurological conditions.
8. Pulmonary embolism: Blood clots can form in the legs or lungs after surgery, potentially causing pulmonary embolism.
9. Anesthesia-related complications: Respiratory and cardiac complications can occur during anesthesia, including respiratory and cardiac arrest.
10. delayed healing: Wound healing may be delayed or impaired after surgery, particularly in patients with pre-existing medical conditions.

It is important for patients to be aware of these potential complications and to discuss any concerns with their surgeon and healthcare team before undergoing surgery.

Symptoms of panniculitis may include pain, swelling, redness, and warmth in the affected area. In severe cases, the skin may become ulcerated and the condition can be accompanied by systemic symptoms such as fever and fatigue.

Panniculitis is often difficult to diagnose, as it can resemble other conditions such as cellulitis or abscesses. A skin biopsy is usually necessary to confirm the diagnosis. Treatment typically involves antibiotics if the condition is caused by an infection, and drainage of any fluid accumulation if there is an abscess. In some cases, surgical debridement may be necessary.

While panniculitis is generally not a life-threatening condition, it can be painful and disruptive to daily activities. It is important to seek medical attention if symptoms persist or worsen over time, as the condition can lead to complications such as infection of the bloodstream (sepsis) or tissue death (necrosis).

Panniculitis can occur at any age but is more common in children and young adults. It is also more prevalent in certain populations such as those with obesity, diabetes, or other chronic conditions that affect the skin.

In summary, panniculitis is a type of inflammation of the subcutaneous fat layer that can be caused by various factors and can present with symptoms such as pain, swelling, redness, and warmth in the affected area. While generally not life-threatening, it can be painful and disruptive to daily activities, and prompt medical attention is necessary for proper diagnosis and treatment.

The endocrine system is a network of glands and hormones that regulate various bodily functions, such as growth, development, metabolism, and reproductive processes. Endocrine system diseases refer to disorders or abnormalities that affect one or more of the endocrine glands or the hormones they produce.

Types of Endocrine System Diseases:

1. Diabetes Mellitus (DM): A group of metabolic disorders characterized by high blood sugar levels due to insulin deficiency or insulin resistance.
2. Hypothyroidism: A condition where the thyroid gland does not produce enough thyroid hormones, leading to symptoms such as fatigue, weight gain, and cold intolerance.
3. Hyperthyroidism: A condition where the thyroid gland produces too much thyroid hormone, leading to symptoms such as anxiety, weight loss, and heart palpitations.
4. Cushing's Syndrome: A rare disorder caused by excessive levels of cortisol hormone in the body, leading to symptoms such as weight gain, high blood pressure, and mood changes.
5. Addison's Disease: A rare disorder caused by a deficiency of cortisol and aldosterone hormones in the body, leading to symptoms such as fatigue, weight loss, and dehydration.
6. Pituitary Gland Disorders: Tumors or cysts in the pituitary gland can affect the production of hormones that regulate other endocrine glands.
7. Adrenal Insufficiency: A condition where the adrenal glands do not produce enough cortisol and aldosterone hormones, leading to symptoms such as fatigue, weight loss, and dehydration.
8. Polycystic Ovary Syndrome (PCOS): A hormonal disorder that affects women of reproductive age, characterized by irregular menstrual cycles, cysts on the ovaries, and insulin resistance.
9. Graves' Disease: An autoimmune disorder that causes hyperthyroidism (an overactive thyroid gland), leading to symptoms such as rapid weight loss, nervousness, and heart palpitations.
10. Hashimoto's Thyroiditis: An autoimmune disorder that causes hypothyroidism (an underactive thyroid gland), leading to symptoms such as fatigue, weight gain, and depression.

These are just a few examples of endocrine disorders, and there are many more that can affect different parts of the endocrine system. It's important to be aware of the signs and symptoms of these disorders so that you can seek medical attention if you experience any unusual changes in your body.

Anti-obesity medication Lemke, Thomas L.; Williams, David A., eds. (2012). "Anorexiants as Pharmacologic Agents in the ... MeSH list of agents 82001067 "European Medicines Agency recommends withdrawal of benfluorex from the market in European Union ... Used on a short-term basis clinically to treat obesity, some appetite suppressants are also available over-the-counter. Most ... Epidemics of fatal pulmonary hypertension and heart valve damage associated with pharmaceutical anorectic agents have led to ...
Oh, Sangmi; Kim, Koon; Chung, Young; Shong, Minho; Park, Seung (2009). "Anti-obesity Agents: A Focused Review on the Structural ... Based on its chemical structure, UWA-101 may actually also possess some activity as a releasing agent, and if so, unlike RTI-83 ... A closely related type of drug is a serotonin-dopamine releasing agent (SDRA). Relative to serotonin-norepinephrine-dopamine ... Hofbauer, Karl (2004). Pharmacotherapy of obesity : options and alternatives. Boca Raton, Fla: CRC Press. ISBN 978-0-415-30321- ...
"Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents". Bioorganic & Medicinal ... Staten, M A (2007). "Challenges in the Discovery and Development of New Agents for the Treatment of Obesity". Clinical ... In 1996, dexfenfluramine became the first long-term treatment anti-obesity medication approved in the US; adverse effects ... Obesity is a global epidemic health problem and has received considerable attention as a major public hazard. Obesity is a ...
Nilsson BM (July 2006). "5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents". Journal of ... It has thermogenic and anorectic effects in animal studies, making it potentially useful for the treatment of obesity. AL-34662 ... Hayashi A, Sonoda R, Kimura Y, Takasu T, Suzuki M, Sasamata M, Miyata K (June 2004). "Antiobesity effect of YM348, a novel 5- ... Smith BM, Thomsen WJ, Grottick AJ (March 2006). "The potential use of selective 5-HT2C agonists in treating obesity". Expert ...
... or weight loss medications are pharmacological agents that reduce or control weight. These medications ... Obesity, Fitness & Wellness Week (14 August 2004). "Legal Issues; Court dismisses claims against anti-obesity medication". ... Cooke D, Bloom S (November 2006). "The obesity pipeline: current strategies in the development of anti-obesity drugs". Nature ... has anti-obesity properties, which may make it useful as a supportive treatment. Accumulating evidence demonstrated anti- ...
"Serotonergic Anti-Obesity Agents". Drugs. 71 (17): 2247-2255. doi:10.2165/11596680-000000000-00000. ISSN 1179-1950. PMID ... Patel, DK; Stanford, FC (March 2018). "Safety and tolerability of new-generation anti-obesity medications: a narrative review ... The artificial distinction between rare monogenic obesity and common polygenic obesity is now obsolete with the identification ... they are a target of choice for anti-obesity drugs development, such as setmelanotide and lorcaserin, but also diabetes, ...
... as a potential antiobesity agent: a randomized controlled trial". JAMA. 280 (18): 1596-600. doi:10.1001/jama.280.18.1596. PMID ... In a study in Zucker rats, which are genetically predisposed to obesity, Garcinia cambogia extract containing HCA showed that ...
... as a Potential Antiobesity Agent: A Randomized Controlled Trial". J. Am. Med. Assoc. 280 (18): 1596-1600. doi:10.1001/jama. ... Journal of Obesity. 2011 (December 14): 509038. doi:10.1155/2011/509038. PMC 3010674. PMID 21197150. "Fruit yellowish or ...
"The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents". Current ... Drinabant reached phase IIb clinical trials for this purpose in the treatment of obesity but was shortly thereafter ... which was under investigation varyingly by Sanofi-Aventis as a treatment for obesity, schizophrenia, Alzheimer's disease, ...
"The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents". Current ... Tim C. Kirkham; S. J. Cooper (2007). Appetite and Body Weight: Integrative Systems and the Development of Anti-Obesity Drugs. ... Heal DJ, Gosden J, Smith SL (December 2009). "Regulatory challenges for new drugs to treat obesity and comorbid metabolic ... and suicidal ideation associated with it and with similarly acting agents. Cannabinoid receptor antagonist Janero DR, ...
... not as an anti-obesity agent. When researchers found out that it promotes less energy uptake, the focus was switched to obesity ... Lipase inhibitors belong to a drug class that is used as an antiobesity agent. Their mode of action is to inhibit gastric and ... For that reason orlistat was chosen over lipstatin for development as an anti-obesity drug. It is the only available FDA- ... Golay A (2000). "The Role of Dietary Fat in Obesity and Therapy with Orlistat.". In Cristophe AB, De Vriese S (eds.). Fat ...
That is why nesfatin-1 has drawn attention as a new therapeutic agent, especially for the treatment of obesity and diabetes ... Thus, Nesfatin-1 acts as a potent Anorexigenic factor (anti-obesity) that improves insulin resistance and opposes weight gain. ... secondary to obesity, ET-1 high level changes on PVAT will lead to PVAT hypertrophy which will be associated with reduced ... Hepatocyte growth factor (HGF) is a mitogen and insulin tropic agent for the β cell. Inadequate β-cell mass can lead to insulin ...
Yukioka H (November 2010). "[A potent and selective neuropeptide Y Y5-receptor antagonist, S-2367, as an anti-obesity agent]". ... was still considered a successful proof of concept of the potential of Y5 receptor antagonists as possible anti-obesity agents ... It has anorectic effects and was developed as a possible treatment for obesity, but was discontinued from further development ... George M, Rajaram M, Shanmugam E (January 2014). "New and emerging drug molecules against obesity". Journal of Cardiovascular ...
... reduces proliferation of colon cancer cells and has been tested as an anti-obesity agent in mice. Limonin has been ... Ono, E.; Inoue, J.; Hashidume, T.; Shimizu, M.; Sato, R. (2011). "Anti-obesity and anti-hyperglycemic effects of the dietary ...
"The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical ... Menendez JA, Vellon L, Lupu R (August 2005). "Antitumoral actions of the anti-obesity drug orlistat (Xenical) in breast cancer ... However, due to its relative simplicity and stability, orlistat was chosen over lipstatin for development as an anti-obesity ... as a potential anti Trypanosoma brucei agent". Chemistry: A European Journal. 18 (27): 8403-8413. doi:10.1002/chem.201200482. ...
... obesity, and chronic weight management. In diabetes it is a less preferred agent compared to metformin. Its effects on long- ... Liraglutide, sold under the brand name Victoza among others, is an anti-diabetic medication used to treat type 2 diabetes, ... Liraglutide is a medication used for the treatment of type 2 diabetes or obesity. Liraglutide improves control of blood glucose ... obesity) or a BMI of 27 or greater (overweight) who have at least one weight-related condition. Liraglutide was approved by the ...
... angiogenesis inhibitors are being investigated for their use as anti-obesity agents, as blood vessels in adipose tissue never ... While the mechanisms of bleeding induced by anti-VEGF agents are complicated and not yet totally understood, the most accepted ... After a series of clinical trials in 2004, Avastin was approved by the FDA, becoming the first commercially available anti- ... Kimura Y, Kido T, Takaku T, Sumiyoshi M, Baba K (September 2004). "Isolation of an anti-angiogenic substance from Agaricus ...
... to other anti-obesity agents, omega-3 gel and not receiving a treatment, the authors could not reach conclusive results due to ... Obesity and overweight adults In 2019 a systematic review compared the effects on weight of various doses of fluoxetine (60mg/d ... It has also been used for cataplexy, obesity, and alcohol dependence, as well as binge eating disorder. Fluoxetine seems to be ...
... anti-diabetic and anti-obesity drug: NCT02905864), Metformin (anti-diabetic drug: NCT04767841, NCT05034029), Zoledronic acid ( ... January 2018). "A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the ... "Osman Kibar lays down his hand at Samumed, stepping away from CEO role as his once-heralded anti-aging biotech rebrands". ... Several approved drugs are being investigated as repurposed agents in the treatment of osteoarhritis such as liraglutide ( ...
... a clinical focus on metabolic rate and the psychological aspects of obesity". ISRN Obesity. 2012: 567530. doi:10.5402/2012/ ... The metabolic rate can be affected by some drugs, such as antithyroid agents, drugs used to treat hyperthyroidism, such as ... has focused on developing antiobesity drugs to raise the metabolic rate, such as drugs to stimulate thermogenesis in skeletal ... New York: Fourth International Conference on Obesity 1983;52(abstr). Webb P. levels of energy exchange in women after ovulation ...
... is an anorectic drug which acts as a norepinephrine-dopamine releasing agent (NDRA). As an amphetamine congener ... Indicated as a short-term secondary treatment for exogenous obesity, phendimetrazine immediate-release 35mg tablets are ... Antiobesity drugs, Anorectics, Phenylmorpholines, Substituted amphetamines, Euphoriants, Norepinephrine-dopamine releasing ... Phendimetrazine possesses preferable pharmacokinetics over phenmetrazine as a therapeutic agent because its metabolization by ...
When comparing, in the same review, the effects of fluoxetine on weight of obese adults, to other anti-obesity agents, omega-3 ... with a BMI 30 to 35 called class 1 obesity; 35 to 40, class 2 obesity; and 40+, class 3 obesity. For children, obesity measures ... "Obesity Policy Action framework and analysis grids for a comprehensive policy approach to reducing obesity". Obesity Reviews. ... The rate of obesity in cats was slightly higher at 6.4%. In Australia the rate of obesity among dogs in a veterinary setting ...
Anti-diabetic drugs, Anti-inflammatory agents, Antineoplastic drugs, Antiobesity drugs, Chemopreventive agents, Organofluorides ... obesity, and traumatic brain injury among others but was ultimately never marketed. It is a modification of DHEA in which the ...
... (INN, codenamed RS-21607) is an anti-obesity drug acting as a lanosterol 14α-demethylase inhibitor. "International ... Antiobesity drugs, Chloroarenes, Dioxolanes, Hypolipidemic agents, Imidazoles, Lanosterol 14α-demethylase inhibitors, ...
Antiobesity drugs, Anorectics, Norepinephrine-dopamine releasing agents, Prodrugs, Stimulants, Substituted amphetamines, Benzyl ... It is prescribed for obesity to people who have been unable to lose weight through exercise and dieting alone. It is a prodrug ... Although the mechanism of action of the sympathomimetic appetite suppressants in the treatment of obesity is not fully known, ...
Antiobesity drugs, Dinitrophenols, Ionophores, Uncoupling agents, Rodenticides, Explosive chemicals, Sweet-smelling chemicals) ... "Mitochondrial uncoupling as a target for drug development for the treatment of obesity". Obesity Reviews. 2 (4): 255-265. doi: ... DNP is listed on the Homeland Security Anti-Terrorism Chemicals of Interest list. DNP is produced by hydrolysis of 1-chloro-2,4 ... "The third lethal case over the last year with the weight loss agent 2,4-dinitrophenol" (PDF). eapcct.org. p. 422. Campos, ...
Another notable agent is rimonabant, a cannabinoid receptor antagonist marketed as an anti-obesity agent which was withdrawn ... and agents with antiandrogen, antiestrogen, and/or anti-neurosteroid activities such as GnRH agonists (e.g., leuprorelin, ...
In 2008, Korean researchers reported DOM could potentially be used as an anti-obesity agent by inhibiting adipocyte ... In 2009, the same Korean researchers published a further study on the anti-obesity and anti-diabetic effects of DOM in obese ... The research suggests that the anti-diabetic and anti-obesity activities of DOM were mediated by modulating the expression of ... Hwang, Hee Sun; Kim, Hyun Ah; Lee, Sung Hak; Yun, Jong Won (2008). "Anti-obesity and Antidiabetic Effects of Deep Sea Water on ...
... to potently induce body-fat loss while preserving protein stores in animals which is the ultimate goal of an anti-obesity agent ... It was first reported in 1996 to cause a body fat loss effect in rats in the International Journal of Obesity and Related ... Weight loss maintenance is one of the most difficult aspects of obesity treatment and so this effect is promising. This led to ... The animal research has all been conducted by the Nitrogen-Obesity Research Group of the University of Barcelona. The compound ...
... anti-inflammatory immunostimulatory, anti-diabetic, anti-obesity, antiviral, antimicrobial, cardioprotective, hepatoprotective ... Turbinaria is utilized for its alginate extracts, which are used as thickening, gelling, and stabilizing agents in food and ... Turbinaria also contains fucoidan, a sulfated polysaccharide with antioxidant, anti-inflammatory, and anticancer properties. ... "The potential of brown-algae polysaccharides for the development of anticancer agents: An update on anticancer effects reported ...
The anti-proprietary party dispatched him to England again to continue the struggle against the Penn family proprietorship. ... Franklin became a national hero in America as an agent for several colonies when he spearheaded an effort in London to have the ... Franklin suffered from obesity throughout his middle-aged and later years, which resulted in multiple health problems, ... One early proponent that Franklin was a member of the Hellfire Club and a double agent is the historian Donald McCormick, who ...
There is a higher risk of blood clots forming in the legs or pelvis - anti-clot stockings or medication may be ordered to avoid ... The WHO does not recommend the use of antispasmodic agents for prevention of delay in labour. For years an episiotomy was ... Risk factors for fetal birth injury include fetal macrosomia (big baby), maternal obesity, the need for instrumental delivery, ... Tsatsaris, Vassilis; Cabrol, Dominique; Carbonne, Bruno (2004). "Pharmacokinetics of tocolytic agents". Clinical ...
... obesity, diabetes, cancer, immune responses, and may be a part of the mechanism of action of the widely-prescribed anti- ... cooperates with Galectin-8-based effects to inactivate mTOR downstream of the lysosomal damaging agents and conditions. The ... Mild lysosomal damage, such as that caused by the anti-diabetes drug metformin may contribute to the therapeutic action of ... "Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity" (PDF). The Journal of ...
Aaseth has studies the effects of disease-modifying agents including anti-TNF-alpha drugs and also selenium compounds. Some of ... Aaseth has been president for the Norwegian Association for the Study of Obesity. Dr. Aaseth has published more than 200 ... Protective measures include the therapeutic use of new iron chelating agents, which have been studied by Aaseth and co-workers ... In particular, he has studied endocrine dysfunctions in obesity, and the impacts of bariatric surgery on the endocrine system. ...
During the early phase of the investigation, much attention and media speculation fell on the anti-obesity supplement AOD-9604 ... to get out of their playing contracts and bypass other AFL player movement restrictions to qualify as delisted free agents, but ... World Anti-Doping Agency v. Thomas Bellchambers et al., Australian Football League, Australian Sports Anti-Doping Authority - ... "Statement on AFL cases". World Anti-Doping Agency. 11 May 2015. "Stephen Dank handed lifetime ban from AFL Anti-Doping Tribunal ...
The Times also noted an "anti-male bias in cancer funding" with a four-to-one discrepancy in the United Kingdom by both the ... The primary risk factors are obesity, age, and family history. Obese men have been found to have a 34% greater death rate from ... For patients with metastatic prostate cancer that has spread to their bones, doctors use a variety of bone-modifying agents to ... "Scientists Discover Anti-Cancer Mechanism that Arrests Early Prostate Cancer". August 4, 2005. Archived from the original on ...
The selective agents (atenolol, metoprolol) are preferred to the non-selective agents (propranolol). There are several ( ... Furthermore, over a fourth of the patients were able to decrease their anti-hypertensive medications and reported symptomatic ... Diabetes and Obesity. 26 (3): 146-154. doi:10.1097/med.0000000000000476. PMID 30893083. S2CID 84844032. Pacak K, Eisenhofer G, ... These agents should be avoided whenever possible as there is upwards of seven times more beta-adrenoceptor antagonism than ...
The main health problems associated with environmental chemical pollutants are asthma, lead poisoning and obesity. It is ... nitrosating agents, and hexavalent chromium. In addition for 160 existing chemicals, under Section 5a2, TSCA requires chemical ... Japanese legislation Chemical Facility Anti-Terrorism Standards (CFATS) - Homeland security laws for chemical storage EPA Makes ... and obesity." Public policy can transform and empower communities "fighting environmental racism" associated with industrial ...
"God the Son" is rejected by anti-trinitarians, who view this reversal of the most common term for Christ as a doctrinal ... obesity, infidelity). Common ideas surrounding sin in various religions include: Punishment for sins, from other people, from ... and can originate directly from God or through an agent, such as an angel. A person recognised as having experienced such ...
... anti-aging treatment, obesity treatment, addiction programs,, and eye surgery. Plastic surgery is also a key sector, and 30% of ... English) Hungary leading in Dental Tourism in Europe, Budapest Agent (English) Hungary aims at bigger bite of dental tourism, ...
"Discovery of protein's configuration could lead to more effective anti-obesity treatments". 23 April 2020. M. Michino, E. Abola ... Structure of the human smoothened receptor bound to an antitumour agent Nature 497: 338-43 Q. Tan, Y. Zhu, J. Li, Z. Chen, G. W ... and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity J Am Chem Soc 119: 681-90; M. ... www.ruiyibio.com https://structuretx.com/ "Structure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical ...
... anti-psychiatry, and feminist movements of the 1970s, but now there is actually no resistance to the advance of government ... or even agents of change. In response to theory based on medicalisation being insufficient to explain social processes, some ... 1 Innumerable other conditions such as obesity, smoking cigarettes, draft malingering, bachelorhood, divorce, unwanted ... arguing that medical authorities had always been concerned with social behavior and traditionally functioned as agents of ...
"Citalopram versus other anti-depressive agents for depression". The Cochrane Database of Systematic Reviews (7): CD006534. doi: ... obesity, and may have a history of trauma or family with GAD. Clinicians use screening tools such as the GAD-7 and GAD-2 ... Like other serotonergic agents, SNRIs have the potential to cause serotonin syndrome, a potentially fatal systemic response to ... Overdose of an SSRI or concomitant use with another agent that causes increased levels of serotonin can result in serotonin ...
Chemotherapy is the treatment of cancer with one or more cytotoxic anti-neoplastic drugs (chemotherapeutic agents) as part of a ... "Obesity and Cancer Risk". National Cancer Institute. 3 January 2012. Archived from the original on 4 July 2015. Retrieved 4 ... Holick MF (January 2013). "Vitamin D, sunlight and cancer connection". Anti-Cancer Agents in Medicinal Chemistry. 13 (1): 70-82 ... Hormones are important agents in sex-related cancers, such as cancer of the breast, endometrium, prostate, ovary and testis and ...
"Discovery of a class of endogenous mammalian lipids with anti-diabetic and anti-inflammatory effects". Cell. 159 (2): 318-32. ... Chemotherapeutic agents such as daunorubicin and etoposide enhance the de novo synthesis of ceramide in studies done on ... 2007). "Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance". ... It has been identified as an anti-inflammatory compound already in 1957, and as an analgesic compound in 1975. Rita Levi- ...
Blavatskyy, Pavlo (2021). "Obesity of politicians and corruption in post-Soviet countries". Economics of Transition and ... for measuring the degree to which human saliva is a good cleaning agent for dirty surfaces. Medical Education: Akira Horiuchi, ... for his pioneering work with anti-gas liquids that prevent bloat, gassiness, discomfort, and embarrassment. Peace - Edward ... Economics: Pavlo Blavatskyy, for discovering that the obesity of a country's politicians may be a good indicator of that ...
Yerevanian A, Soukas AA (June 2019). "Metformin: Mechanisms in Human Obesity and Weight Loss". Current Obesity Reports. 8 (2): ... A New Hypoglycemic Agent". J Am Chem Soc. 81 (9): 2220-25. doi:10.1021/ja01518a052. "Procédé de préparation de chlorhydrate de ... Rosilio C, Ben-Sahra I, Bost F, Peyron JF (May 2014). "Metformin: a metabolic disruptor and anti-diabetic drug to target human ... Some evidence shows that metformin is associated with weight loss in obesity in the absence of diabetes. Metformin has a lower ...
Endoscopic Duodenal-Jejunal Bypass Sleeve Treatment for Obesity". In Agrawal S (ed.). Obesity, Bariatric and Metabolic Surgery ... esomeprazole A cytoprotectant and acid buffering agent, e.g. sucralfate Temporary restriction of the consumption of solid foods ... Anastomosis tension Gastric acid The bacteria Helicobacter pylori Smoking Use of non-steroidal anti-inflammatory drugs This ... Gastric bypass is indicated for the surgical treatment of morbid obesity, a diagnosis which is made when the patient is ...
... but clinical experience with these newer agents is not as developed as that with the older agents. The mechanism of these ... "Treatment with the 5-HT3 antagonist tropisetron modulates glucose-induced obesity in mice". International Journal of Obesity. ... The atypical anti-psychotic paliperidone was approved by the FDA in late 2006.[citation needed] The atypical antipsychotics ... Sexual adverse effects caused by some anti-psychotics are a result of an increase of prolactin. Sulpiride and Amisulpiride, as ...
Bariatrics Obesity Childhood obesity Orexigenic Epidemiology of obesity Epidemiology of childhood obesity Calafat AM, Kuklenyik ... Organotins (tin-based chemicals), used in marine anti-fouling paints, wood catalysts, plasticizers, slimicides, in industrial ... with nicotine as the single causal agent. Arsenic is a metalloid (i.e., an element with some metallic properties) found in and ... Obesity has become a pandemic, increasing for all population groups. From 1980 to 2008, the rates of obesity have doubled for ...
Risk of septic arthritis increases with anti-tumor necrosis factor alpha treatment. Immunosuppressive medication Intravenous ... The risk factors of prosthetic joint infections are: previous fracture, seropositive rheumatoid arthritis, obesity, revision ... or joint infection is the invasion of a joint by an infectious agent resulting in joint inflammation. Generally speaking, ...
Obesity, in particular a body mass index greater than 35-40, is associated with greater amounts of viral replication, increased ... Initially, the microbial agent responsible for influenza was incorrently identified in 1892 by R. F. J. Pfeiffer as the ... Treatment of influenza in cases of mild or moderate illness is supportive and includes anti-fever medications such as ... Just two years after influenza viruses were discovered, in 1933, IAV was identified as the agent responsible for human ...
... these metabolites are members of the specialized proresolving mediator class of anti-inflammatory agents that contribute to the ... in the insulin resistance that occurs in obesity that is associated with diabetes and the metabolic syndrome; and in ... These products may be further metabolized to: Resolvin E3, a specialized proresolvin mediator with anti-inflammatory activity ( ... These metabolites have been reported to have anti-inflammatory activity, to have vasodilationactivity, to promote pain ...
Canada's obesity rate of 14.3% is about half of that of the United States 30.6%. On average, obesity reduces life expectancy by ... "Anti-medicare ad an exaggeration: experts". CBC News. July 31, 2009. Archived from the original on August 3, 2009. Retrieved ... September 2007). "The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with ... "Adult obesity in Canada: Measured height and weight". Statcan.ca. November 16, 2008. Archived from the original on October 12, ...
... but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota". Cell Reports. ... Such organisms are raised using various methods to control their exposure to viral, bacterial or parasitic agents. When known ... Gérard, Philippe (November 2017). "Gut Microbiome and Obesity. How to Prove Causality?". Annals of the American Thoracic ... obesity, and metabolic disease". Genome Medicine. 8 (1): 42. doi:10.1186/s13073-016-0303-2. PMC 4839080. PMID 27098727. Round ...
"Leveraging social influence to address overweight and obesity using agent-based models: The role of adolescent social networks ... By modeling a complex system of analysts based on three distinct behavioral profiles - imitating, anti-imitating, and ... "Agents for Systems." Systems for Agents (sometimes referred to as agents systems) are systems implementing agents for the use ... Agent-based modeling is related to, but distinct from, the concept of multi-agent systems or multi-agent simulation in that the ...
Due to the change on hormones, the use of these agents can also effect athletes metabolism. Diuretics and masking agents: ... Anti-doping policy within tennis primarily developed from the 1980s with the increased prevalence of recreational drugs and ... The substance is widely prescribed to sufferers of obesity and diabetes with the main effect of the drug being an appetite ... Anti-doping policy remains controversial due to the large amount of substances, ingredients and chemicals that athletes are ...
"Fears of new virus trigger anti-China sentiment worldwide". The Korea Times. 2 February 2020. "Coronavirus fuels anti-Chinese ... The strongest risk factors for severe illness are obesity, complications of diabetes, anxiety disorders, and the total number ... International Journal of Antimicrobial Agents. 55 (6): 105948. doi:10.1016/j.ijantimicag.2020.105948. PMC 7156162. PMID ... "Coronavirus: Anti-Lockdown Protests Grow Across US". BBC News. 17 April 2020. Archived from the original on 17 April 2020. ...
Start Over You searched for: Subjects Anti-Obesity Agents -- therapeutic use ✖Remove constraint Subjects: Anti-Obesity Agents ... 1. Expanding access to obesity treatments for older adults Publication: Washington, D.C. : Bipartisan Policy Center, February ...
Doggrell, S. A. Alpha-lipoic acid, an anti-obesity agent? Expert.Opin.Investig.Drugs 2004;13:1641-1643. View abstract. ... Amelioration of lipid abnormalities by a-lipoic acid through antioxidative and anti-inflammatory effects. Obesity (Silver ... Medications for cancer (Alkylating Agents). Alpha-lipoic acid is an antioxidant. There is some concern that antioxidants might ... Obesity. Taking alpha-lipoic acid by mouth can slightly reduce body weight in adults who are overweight. ...
Anti-Obesity Agents / adverse effects* Actions. * Search in PubMed * Search in MeSH ...
Obesity management is a modern challenge because of the rapid evolution of unfavorable lifestyl … ... Obesity is reaching epidemic proportions worldwide and it is correlated with various comorbidities, among which the most ... Anti-Obesity Agents / administration & dosage Actions. * Search in PubMed * Search in MeSH ... Pharmacological therapy of obesity] [Article in Italian] Uberto Pagotto 1 , Diego Vanuzzo, Valentina Vicennati, Renato Pasquali ...
Anti-Obesity Agents/administration & dosage; Anti-Obesity Agents/pharmacology; Anti-Obesity Agents/therapeutic use*; ... Obesity/drug therapy*; Obesity/etiology; Obesity/metabolism; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1- ... on BAT activation in the development of diet-induced obesity and metabolic disorders via osmotic minipump delivery in mice. ... 20-EDP Combined with Soluble Epoxide Hydrolase Inhibitor t-TUCB on Diet-Induced Obesity in Mice. ...
... in future agent-based models of obesity. Moreover, agent-based models of obesity could be more useful if they took into account ... El-Sayed AM, Seemann L, Scarborough P, Galea S. Are network-based interventions a useful antiobesity strategy? An application ... Obesity. Most agent-based models of obesity focused on the impact of social influences (peer effects) on the dynamics of ... Key Properties of Agent-Based Modeling of Chronic Diseases. Property. Description. Interactive. Agents can interact with each ...
Anti-Obesity Agent Anti-Obesity Drug Anti-Obesity Drugs Antiobesity Agent Antiobesity Agents Antiobesity Drug Antiobesity Drugs ... Anti-Inflammatory Agents [D27.505.954.158] * Anti-Obesity Agents [D27.505.954.203] * Appetite Depressants [D27.505.954.203.155] ... Anti-Obesity Agents Preferred Concept UI. M0028922. Registry Number. 0. Scope Note. Agents that increase energy expenditure and ... Anti-Obesity Agents Preferred Term Term UI T057960. Date01/01/1999. LexicalTag NON. ThesaurusID NLM (1997). ...
Acidifying agents- Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices ... Exogenous Obesity Usual dosage is up to 30 mg daily, taken in divided doses of 5 to 10 mg, 30 to 60 minutes before meals. Not ... Lithium carbonate- The antiobesity and stimulatory effects of amphetamines may be inhibited by lithium carbonate. ... Alkalinizing agents- Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines. ...
Diseases : Cardiovascular Diseases, Hypertension, Inflammation, Obesity. Pharmacological Actions : Anti-Inflammatory Agents, ... Pharmacological Actions : Anti-Apoptotic, Anti-Inflammatory Agents, Antioxidants, Neuroprotective Agents. Problem Substances : ... Pharmacological Actions : Anti-Inflammatory Agents, Antioxidants, Cardiovascular Agents, Neuroprotective Agents. Additional ... Diseases : Hypertension, Inflammation, Obesity, Oxidative Stress. Pharmacological Actions : Anti-Inflammatory Agents, ...
D009767 - Obesity, Morbid, D009765 - Obesity, D019440 - Anti-Obesity Agents, D000073319 - Obesity Management ... Patients with obesity and GERD symptoms should be evaluated by endoscopy if medical treatment fails to control symptoms. (II, B ... In most populations a cutoff point of ≥25 kg/m2 should be used to initiate further evaluation of overweight or obesity. (II, A) ... In patients with obesity and alcohol or other addictions, consider using orlistat or liraglutide 3 mg. (I, A) ...
Fu C, Jiang Y, Guo J, Su Z. Natural products with anti-obesity effects and different mechanisms of action. J Agric Food Chem ... as a potential antiobesity agent: a randomized controlled trial. JAMA 1998;280:1596-600. [PubMed abstract] ... Oral intake of a combination of glucosyl hesperidin and caffeine elicits an anti-obesity effect in healthy, moderately obese ... Capsaicin and other capsaicinoids have been proposed to have anti-obesity effects via their ability to increase energy ...
SIR sibutramine an antiobesity agents this treatment for obesity in obese subjects who lose weight. Sibutramine does not assume ... Obesity June 1 2005. They do not take only the next two weeks of the drug or alcohol problems. Hypertens 17 suppl. Overall cost ... Grundy SM, obesity. They do not in, vitro. Cordeiro as the triptans because of this website. Independent evaluations of 154/87 ... A 50 year! Baseline lipid levels in the sibutramine and treatment of obesity. Pagano and, 0% placebo. These trials may not be ...
An extract of C. fimbriata (Slimaluna( ), Gencor Nutrients, Anaheim, CA, USA) is used as an anti-obesity agent and appetite ... A commercially available extract of CFE in an oral dose of 1 g/day claimed to have anti-obesity effect failed to yield any ... This coupled with the GRAS status of the extract of C. fimbriata has opened the possibility of developing an anti-obesity/ ... It is also seen that the pregnane glycosides isolated and identified from African Hoodia are reported as anti-obesity and ...
... through pre-prandial receptor blockade may represent the most promising role of ghrelin as a useful future anti-obesity agent. ... Anti Appetite Suppressants? The field of vision of the other party is comparable to that of the god-destroying demon, and best ... Obesity is a serious problem on a global scale and has a tendency of constant rising- an issue that triggers doctors, ... Tami Center said, You were imprisoned here during the Qinhuai anti appetite suppressants better weight loss keto pills have ...
... supplemental DHEA has been shown to have anti-aging, anti-obesity and anti-cancer influences. In addition, it is known to ... Schwartz AG, Hard GC, Pashko LL, Abou-Gharbia M and Swern D. Dehydroepiandrosterone: An antiobesity and anti-carcinogenic agent ... The Anti-Obesity Factor. At about the same time that Schwartz was investigating the anti-cancer properties of DHEA, Dr. ... Prevention of obesity in Avy/a mice by dehydroepiandrosterone. Lipids 12: 409-13, 1977.. 5. Cleary MP and Fisk JF. Anti-obesity ...
Source: Gordon J, McEwan P, Bron M, Ward T. The economics of anti-obesity treatment: evaluating the budget impact to payers in ... 1 oral antipsychotic agent at different times; and (4) an oral stable group, which included patients using 1 oral antipsychotic ... The estimates for the number of patients who would be eligible for anti-obesity therapies were based on the US National Health ... Overall, the addition of naltrexone-bupropion to the anti-obesity therapies on a formulary would result in a cost of less than ...
Agents, Anti-Obesity Agents, Antiobesity Anti Obesity Agents Anti Obesity Drugs Anti-Obesity Agent Anti-Obesity Drug Anti- ... Agents, Antiobesity. Agents, Weight-Loss. Anti Obesity Agents. Anti Obesity Drugs. Anti-Obesity Agent. Anti-Obesity Drug. Anti- ... Obesity Drugs Antiobesity Agent Antiobesity Agents Antiobesity Drug Antiobesity Drugs Drugs, Anti-Obesity Drugs, Antiobesity ... Antiobesity Agent. Antiobesity Agents. Antiobesity Drug. Antiobesity Drugs. Drugs, Anti-Obesity. Drugs, Antiobesity. Drugs, ...
Anti-Obesity Agent Anti-Obesity Drug Anti-Obesity Drugs Antiobesity Agent Antiobesity Agents Antiobesity Drug Antiobesity Drugs ... Anti-Inflammatory Agents [D27.505.954.158] * Anti-Obesity Agents [D27.505.954.203] * Appetite Depressants [D27.505.954.203.155] ... Anti-Obesity Agents Preferred Concept UI. M0028922. Registry Number. 0. Scope Note. Agents that increase energy expenditure and ... Anti-Obesity Agents Preferred Term Term UI T057960. Date01/01/1999. LexicalTag NON. ThesaurusID NLM (1997). ...
... it should be evaluated for use as an effective weight-loss method and as a new therapeutic agent targeting obesity.(AU). O ... Additionally, consumption of Gundelia tournefortii L. plant extract in the diet may have antiobesity effects; thus, ... antioxidant activities and DNA damage in a rat model of experimental obesity / Efeitos de Gundelia tournefortii L. em ...
Piperine is an anti-obesity agent that reduces the accumulated fat in 4 weeks, according to the Japanese Study conducted by ...
Anti-Infective Agents, Urinary, Anti-Inflammatory Agents, Obesity, Urinary Tract, Urinary Tract Physiological Phenomena, Anti- ... Bacterial Agents, Human Rights, Renal Dialysis, Dialysis, Bone Diseases, Health Policy, Chronic Disease, Renal Insufficiency, ... Obesity, Body Weight, Diet, Reducing, Endocrinology, Endocrine System Diseases, Diagnostic Techniques, Endocrine, Metabolism, ... Obesity, Infertility, Menopause, Diabetes, Fenômenos Bioquímicos, Metabolismo e Nutrição, Tecnologia Médica, Técnicas e ...
Food components with thermogenic properties are promising antiobesity agents. Ginger (Zingiber officinale Rosc.) bioactive ... Metabolic and behavioral effects of time-restricted eating in women with overweight or obesity: Preliminary findings from a ... and eating disorders and weight loss in women with overweight or obesity. METHODS: Women age 18 to 59 y with a body mass index ... This study showed that 8 wk of TRE does not influence behavioral parameters in individuals with overweight or obesity, but ...
The key gastrointestinal diseases drug categories include Anti-peptic agents (antacids, antagonists, Proton Pump Inhibitors, ... The reason for this increase can be attributed to factors such as a low-fiber diet, obesity, and consumption of alcohol and ... anti thrombotics, and other drugs for cardiovascular diseases (congestive heart failure, anti-arrhythmic and anti-anginal drugs ... Anti Thrombotics, Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic And Anti-Anginal Drugs)), ...
Know Allen A39 Anti Obesity Drops(30 ml) price, specifications, benefits and other information only on emedicinehub.com ... Buy Allen A39 Anti Obesity Drops(30 ml) online at best price in India. ... It is a diuretic and detoxifying agent. It burns excess fat and sugar. ... Allen A39 Anti Obesity Drops (30 ml). Helps in managing excess Weight, Thyroid, regulate digestion, weakness ...
... help manage obesity, diabetes and metabolic syndrome, and offer a wealth of anti-inflammatory agents to treat chronic disease.[ ... Research also shows it may have anti-cancer properties and use for conditions ranging from obesity and diabetes to depression. ... Devils Claw: Devils Claw is most widely known for its anti-inflammatory, anti-rheumatic and pain-relieving properties, ... Boswellia: Boswellia, a key part of Heal-n-Soothe, has demonstrated powerful anti-inflammatory and immune system effects for ...
Anti-Infective Agents, Urinary, Anti-Inflammatory Agents, Obesity, Urinary Tract, Urinary Tract Physiological Phenomena, Anti- ... HIV, Acquired Immunodeficiency Syndrome, Anti-HIV Agents, HIV Long-Term Survivors, AIDS Serodiagnosis, Sexuality, Sexually ... Bacterial Agents, Human Rights, Renal Dialysis, Dialysis, Bone Diseases, Health Policy, Chronic Disease, Renal Insufficiency, ...
Anti-Obesity Agents [D27.505.954.203] * Appetite Depressants [D27.505.954.203.155] Expand All Collapse All Appetite Depressants ... Agents that are used to suppress appetite.. Entry Version. APPETITE DEPRESS. Entry Term(s). Anorectic Anorectic Agent Anorectic ... Agents that are used to suppress appetite.. Terms. Appetite Depressants Preferred Term Term UI T003238. Date01/01/1999. ... Anorectic Agents Term UI T761884. Date12/03/2009. LexicalTag NON. ThesaurusID NLM (2011). ...
  • Obesity is reaching epidemic proportions worldwide and it is correlated with various comorbidities, among which the most relevant are diabetes mellitus, arterial hypertension, and cardiovascular diseases. (nih.gov)
  • The current medical attitude is to treat the complications of obesity (e.g. dyslipidemia, hypertension, diabetes, and cardiovascular diseases). (nih.gov)
  • Americans are facing a growing burden of chronic disease that includes heart disease, stroke, diabetes, and obesity. (cdc.gov)
  • This article 1) introduces the concept of agent-based modeling - a relatively new systems science methodology, 2) reviews existing agent-based modeling of several prevalent chronic diseases (ie, diabetes, cardiovascular disease, obesity), 3) identifies barriers to adopting agent-based modeling to study chronic diseases, and 4) proposes novel research directions in this promising field that can lead to informed policy and practice. (cdc.gov)
  • Due to variable risk for future diabetes, patients with overweight or obesity should be evaluated for risk of T2DM, which can be estimated or stratified using indices or staging systems that employ clinical data, glucose tolerance testing, and/or metabolic syndrome traits. (guidelinecentral.com)
  • Dominant kapha may predispose you to diabetes, cancer, obesity and asthma. (losethebackpain.com)
  • Modern research into Ayurveda is promising, with research suggesting it may work to treat rheumatoid arthritis as well as drugs (but with fewer side effects), help manage obesity, diabetes and metabolic syndrome, and offer a wealth of anti-inflammatory agents to treat chronic disease. (losethebackpain.com)
  • On the basis of some of its many actions, it has also been developed into a pharmaceutical agent for the treatment of obesity and type 2 diabetes (T2DM). (healthworldnet.com)
  • Summary Insulin resistance is a chronic inflammatory condition accompanying obesity or high fat diets that leads to type 2 diabetes. (cyberleninka.org)
  • This 3-phase paradigm for chronic disease aligns with the pathophysiology and natural history of obesity and provides a rational framework for appropriate treatment at each phase of prevention. (guidelinecentral.com)
  • Interested in receiving weekly updates about the Obesity, Metabolic Syndrome, and Prediabetes Center of Excellence? (practiceupdate.com)
  • Our virtual center of excellence in the treatment of Obesity, Metabolic Syndrome, and Prediabetes leverages technology to create a collaborative and comprehensive way to improve patient care. (practiceupdate.com)
  • The study concluded that Clenbuterol works with similar or similar mechanisms of action to those of the appetite suppressing agent bariatric surgery and has several therapeutic advantages. (artrakimya.com)
  • The principal outcome and therapeutic target in the treatment of obesity should be to improve the health of the patient by preventing or treating weight-related complications using weight loss, not the loss of body weight per se. (guidelinecentral.com)
  • thus, it should be evaluated for use as an effective weight-loss method and as a new therapeutic agent targeting obesity. (bvsalud.org)
  • It has been established that obesity alters the metabolic and endocrine function of adipose tissue and, together with accumulation of adipose tissue macrophages, contributes to insulin resistance. (elsevier.com)
  • Here, we determined whether cytotoxic T-lymphocyte-associated antigen-4IgG1 (CTLA-4Ig) can ameliorate insulin resistance by induction of macrophages from proinflammatory M1 to anti-inflammatory M2 polarization in the adipose tissues of high fat diet-induced insulin-resistant mice. (elsevier.com)
  • This novel mechanism of CTLA-4lg immunotherapy may lead to an ideal anti-obesity/inflammation/insulin resistance agent. (elsevier.com)
  • Patients with T2DM should be evaluated for the presence of overweight or obesity. (guidelinecentral.com)
  • Drug treatment for obesity is an evolving branch of pharmacology, burdened by severe side effects and consequences of the early drugs, withdrawn from the market, and challenged by the lack of long-term data on the effect of medications on obesity-related morbidity and mortality, first of all cardiovascular diseases. (nih.gov)
  • Drugs in this class used in obesity are commonly known as "anorectics" or "anorexigenics. (nih.gov)
  • It has not been established, however, that the action of such drugs in treating obesity is primarily one of appetite suppression. (nih.gov)
  • And finally, every individual s body responds differently to different drugs, so it s possible that Zoloft won t work for you, in which case you may need to find an effective?alternative anti-anxiety treatment method. (jewishledger.com)
  • Obesity management is a modern challenge because of the rapid evolution of unfavorable lifestyles and unfortunately there are no effective treatments applicable to the large majority of obese/overweight people. (nih.gov)
  • A commercially available extract of CFE in an oral dose of 1 g/day claimed to have anti-obesity effect failed to yield any positive results on anthropometry and appetite in overweight and obese individuals beyond placebo. (raysahelian.com)
  • At about the same time that Schwartz was investigating the anti-cancer properties of DHEA, Dr. Terrence T. Yen was studying the effect of DHEA on genetically obese mice. (directlabs.com)
  • Anti-obesity effect of two different levels of dehydroepiandrosterone in lean and obese middle-aged female Zucker rats. (vitaminwiki.net)
  • Badheka AO, Rathod A, Kizilbash MA, Garg N, Mohamad T, Afonso L, Jacob S. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. (nih.gov)
  • Obesity also has been linked with increased incidence of atrial fibrillation, but its influence on outcomes in atrial fibrillation patients has not been investigated. (nih.gov)
  • The objective of this research is to investigate the effect of obesity on outcomes in atrial fibrillation. (nih.gov)
  • CONCLUSIONS: Although in prior studies, obesity has been associated with increased risk of atrial fibrillation, an obesity paradox exists for outcomes in atrial fibrillation. (nih.gov)
  • Agents that are used to suppress appetite. (nih.gov)
  • In most populations a cutoff point of ≥25 kg/m 2 should be used to initiate further evaluation of overweight or obesity. (guidelinecentral.com)
  • BMI should be used to confirm an excessive degree of adiposity and to classify individuals as having overweight (BMI 25 to 29.9 kg/m 2 ) or obesity (BMI ≥30 kg/m 2 ), after taking into account age, gender, ethnicity, fluid status, and muscularity. (guidelinecentral.com)
  • More than two-third of adults and almost one-third of children and adolescents in the United States are overweight or have obesity [ 1 , 2 ]. (nih.gov)
  • Forty-five percent of Americans who are overweight and 67% of those with obesity are trying to lose weight [ 3 ]. (nih.gov)
  • Anti-obesity medications may help with weight and perhaps the liver. (gutsandgrowth.com)
  • Although the specific mechanisms of action for DHEA are only partially understood, supplemental DHEA has been shown to have anti-aging, anti-obesity and anti-cancer influences. (directlabs.com)
  • The reason for this increase can be attributed to factors such as a low-fiber diet, obesity, and consumption of alcohol and tobacco, among others. (thebusinessresearchcompany.com)
  • This article introduces agent-based modeling by providing a narrative review of agent-based models of chronic disease and identifying the characteristics of various chronic health conditions that must be taken into account to build effective clinical- and policy-relevant models. (cdc.gov)
  • It is also used for obesity, altitude sickness, aging skin, high levels of cholesterol or other fats in the blood, and many other purposes, but there is no good scientific evidence to support many of these other uses. (medlineplus.gov)
  • Agents that increase energy expenditure and weight loss by neural and metabolic regulation. (nih.gov)
  • Approved agents for adolescents include 1) Orlistat -safe, but frequent side effects (eg. (gutsandgrowth.com)
  • Anti-tumor effects of cold atmospheric pressure plasma on vestibular schwannoma demonstrate its feasibility as an intra-operative adjuvant treatment. (harvard.edu)
  • Agents (eg, individuals, organizations) in an agent-based model may be endowed with a large set of "real-world" properties ( Table ). (cdc.gov)
  • It comes with some great anti obesity properties that manipulate your body shape. (hashnode.dev)
  • HN - 2019 (1980) MH - 5-Methoxypsoralen UI - D000078223 MN - D3.383.663.283.446.794.688 MN - D3.633.100.150.446.794.688 MN - D3.633.300.770.688 MS - A linear furanocoumarin that has phototoxic and anti-inflammatory properties, with effects similar to METHOXSALEN. (nih.gov)
  • In many populations, a waist circumference cutoff point of ≥94 cm in men and ≥80 cm in women should be considered at risk and consistent with abdominal obesity. (guidelinecentral.com)
  • In South Asian, Southeast Asian, and East Asian adults, men with values ≥85 cm and women ≥74 to 80 cm should be considered at risk and consistent with abdominal obesity. (guidelinecentral.com)
  • The Apple cider components and BHB is very vital in taking away the risk of obesity. (hashnode.dev)
  • With all the studies from China and the USA proving that Clenbuterol is an effective weight loss agent, it's time for the government to take the next step and regulate its availability. (artrakimya.com)
  • Taking alpha-lipoic acid by mouth with or without standard hydration therapy during a coronary angiography doesn't seem to prevent kidney damage caused by contrast agents. (medlineplus.gov)
  • Clenbuterol is a powerful anti-obesity agent, clenbuterol weight loss results reddit. (artrakimya.com)
  • Agent-based models can be used to uncover complex causal effects, identify underlying mechanisms behind complex systems, and make sense of large amounts of existing evidence and data. (cdc.gov)
  • The conclusion from these researches was that Clenbuterol is an effective weight loss agent for weight-loss, especially when ingested by a healthy person over a long period of time, clenbuterol weight loss 2 weeks. (artrakimya.com)
  • The study concluded that Clenbuterol is an effective weight loss agent and is safe, clenbuterol weight loss tips. (artrakimya.com)
  • In addition, the fast growth of agent-based modeling software, such as NetLogo (The Center for Connected Learning and Computer-Based Modeling, Northwestern University), Repast (Argonne National Laboratory), Swarm (Swarm Development Group), and AnyLogic (The AnyLogic Company), has simplified the model development process and facilitated the use of agent-based modeling in various fields. (cdc.gov)
  • Systems science methodologies such as system dynamics, discrete-event simulation, network analysis, and agent-based modeling have the potential to inform decision makers on how chronic health conditions develop and their consequences. (cdc.gov)
  • Agent-based modeling is a promising systems science approach that can model complex interactions and processes related to chronic health conditions, such as adaptive behaviors, feedback loops, and contextual effects. (cdc.gov)
  • If you want to become thinner without investing any chemical agents in your body, this is the option to choose. (hashnode.dev)
  • Finally, we discuss future research directions of agent-based modeling applied to problems related to specific chronic health conditions. (cdc.gov)
  • Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage. (harvard.edu)
  • This study investigates the preventive effects of t-TUCB (T) alone or combined with 19,20-EDP (T + EDP) or 17,18-EEQ (T + EEQ) on BAT activation in the development of diet-induced obesity and metabolic disorders via osmotic minipump delivery in mice. (nih.gov)